Podcasts about pharmaceutics

Welcome to another episode of On the Couch, the podcast series where we chat with brokers, CEOs, and fund managers to give you valuable insights into the investing world.In this episode, Henry Jennings is joined by Dr Nina Webster, CEO and Managing Director of Dimerix (ASX: DXB), a clinical-stage biopharmaceutical company working on treatments for inflammatory diseases. With a market cap of $270 million, Dimerix is advancing its proprietary Phase 3 candidate DMX-200 to treat Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease, and is also developing DMX-700 for respiratory disease.Nina has over 30 years of experience in the pharmaceutical industry, with leadership roles across research, development, and commercialisation. She was formerly Commercial Director at Acrux (ASX: ACR), an Australian pharmaceutical company that successfully developed and commercialised multiple products globally. She is also Non-Executive Chairperson for SYNthesis BioVentures and a Non-Executive Director at Linear Clinical Research Limited. Dr Webster holds a Ph.D in Pharmaceutics from Cardiff University, a Bachelor's degree in Pharmacology, a Master's in Intellectual Property Law from Melbourne University, and an Executive MBA from RMIT.Talking Points:Dimerix is focused on developing and commercialising new treatments for inflammatory diseases with poor outcomes. The leading drug candidate is a treatment for a rare kidney disease known as FSGS - what's the nature of this disease and its current treatment?What's changed, and how did DXB come about?DMX-200 is now in a global Phase 3 clinical trial - an update on the trial and when results are expected.The upside from here following DXB's strong run.Are all the eggs in one basket if this trial is not successful? What is Plan B?Three successful commercial deals - how they came together.CEOs shouldn't speculate on future licensing deals, but the US market is always the big one. What interest has there been from US pharma companies?How does what's happening in the US impact Dimerix? Elon Musk has been vocal about the FDA, and with Kennedy in charge, is there extra risk of regulatory slowdowns?NEU as a playbook - Dr Webster previously worked with NEU's CEO at Acrux. Is Dimerix a bona fide Neuren replica?Cash reserves and burn rate - what's the current financial position?Who are Dimerix's biggest shareholders?If the FSGS trial goes well, what happens next? Licensing?What will be the major Dimerix milestones for 2025?A deep dive into Dimerix, the biotech sector, and what's ahead for the company.Listen now to hear the full conversation.Disclaimer: This is general advice only. Please consult your financial adviser before making any investment decisions.If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you.Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Dive into the world of bio-aesthetics with Dr. Bill Dorfman and Chairman of Carmell Corporation, Rajiv Shukla Raj Shu on this episode of Meet the Mentor, Discover Carmel Corporation's innovative approach to skincare as Rajiv Shukla shares insights from his illustrious career, spanning leadership roles in major healthcare companies like Pfizer and Morgan Stanley. Explore how Carmell is revolutionizing skincare by using biological proteins instead of chemicals for a more natural rejuvenation process. ABOUT THE GUEST Rajiv Shukla is Chairman of Carmell Corporation, a revolutionary bio-aesthetics company. Over his 20+ year career, he has served as CEO of 4 public companies, and as Director on the boards of 14 companies. He has led 3 Nasdaq IPOs and multiple PIPEs that have collectively raised over $650 million in financing. He has been involved with over 45 healthcare investments and over $65 billion in M&A. Rajiv has served as Managing Director/Portfolio Manager at Morgan Stanley Investment Management, Private Equity Director at Citi Venture Capital International and led Global M&A at Pfizer's R&D division. He graduated with a Master's in Healthcare Management from Harvard University and a Bachelors in Pharmaceutics from the Indian Institute of Technology. ABOUT THE HOST Dr. Bill Dorfman is not just a famous cosmetic and general dentist, he is THE most famous cosmetic dentist world wide. Affectionately known as “America's Dentist,” Dr. Bill is widely recognized world-wide as a leading dentist who is responsible for creating smiles for many of Hollywood's brightest stars. In fact, Dr. Dorfman has become a star in his own right as the featured dentist on the hit ABC series, “Extreme Makeover,” where he performed amazing dental transformations on the show's participants as well as a recurring guest co-host on the new Emmy Winning daytime CBS talk show, “The Doctors.” In addition, Dr. Dorfman is a world-renowned lecturer & author of the best-selling cosmetic dentistry book, The Smile Guide and the NY Times bestseller Billion Dollar Smile. The innovative & accomplished doctor is also renowned in his field as an energy-brimming inventor & brilliant entrepreneur who has brought award-winning innovations to the world of dentistry. Dr. Bill Dorfman has been interviewed extensively for numerous television shows & magazines including ABC's Good Morning America, The View, Oprah, CNN's Larry King Live, NBC's The Today Show, The Tonight Show with Jay Leno, Dr. Phil, The Rachael Ray Show, Steve Harvey Show, FABLife, The Doctors, The Tyra Banks Show, Ricki Lake Show, Entertainment Tonight, MTV's The Osbournes & Newlyweds: Nick & Jessica, The Wayne Brady Show, The Sharon Osbourne Show, Living It Up! With Ali & Jack, EXTRA, Soap Talk, Access Hollywood & E! Entertainment Television. Learn more about your ad choices. Visit megaphone.fm/adchoices

Dr. Seth Lederman, CEO of Tonix Pharmaceuticals, recently shared key findings with Steve Darling from Proactive following the company's presentations at the 11th Global Conference on Pharmaceutics and Novel Drug Delivery Systems in Rome. The presentations detailed the eutectic formation of cyclobenzaprine HCl and mannitol, highlighting its stability and rapid dissolution, allowing for efficient transmucosal delivery of cyclobenzaprine into the bloodstream. This innovative formulation protects the drug from interacting with the basifying agent needed for absorption, offering a more effective delivery system. Dr. Lederman emphasized the ongoing unmet need for fibromyalgia treatments, with many patients unsatisfied with current options. Tonix's lead candidate, TNX-102 SL, has shown significant potential as a once-daily bedtime treatment that could provide broad-spectrum symptom relief for fibromyalgia patients. With promising results from two Phase 3 studies, TNX-102 SL is positioned to become the first new treatment for fibromyalgia in 15 years, offering hope to millions of patients seeking better management of their symptoms. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Fibromyalgia #TNX102SL #FDAApproval #DrugDevelopment #PharmaceuticalInnovation #BiotechNews #ClinicalTrials #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Episode 148: Amardeep Parmar (https://www.linkedin.com/in/amardeepsparmar) from The BAE HQ (https://www.linkedin.com/company/the-bae-hq) welcomes Rina Newton, Co-Founder of Code Clarity.“I didn't know corporate pharmacy even existed” - Rina Newton. After working in hospital and retail pharmacy obtaining a PhD and lecturing Rina still didn't find something she truly enjoyed.Until a fluke occurred and she stumbled into corporate pharmacy. Being only one of the few who revelled in understanding the complex Pharma compliance Code book, she identified a gap in the market in helping other Pharma directors and companies better navigate compliance in the sector.This led to CompliMed and now Code Clarity. Rina also now uses her experience, platform and networks to help female asian founders particular in the life sciences Message from our headline partners:From the first time founders to the funds that back them, innovation needs different. HSBC Innovation Banking is proud to accelerate growth for tech and life science businesses, creating meaningful connections and opening up a world of opportunity for entrepreneurs and investors alike. Discover more at https://www.hsbcinnovationbanking.com/________Rina Newton https://www.linkedin.com/in/rinanewton/Code Clarity: https://www.linkedin.com/company/code-clarity-uk/Visit our website:https://www.thebaehq.com/

Send us a Text Message.Dr. Xiaorong He, Ph.D., MBA is Senior Vice President, Head of Global Development Sciences and U.S. Site Head of Non-Clinical Development at Boehringer Ingelheim Pharmaceuticals, Inc. ( https://www.boehringer-ingelheim.com/us ), where with over two decades of experience, her leadership focus lies in advancing transformative medicinal product development and fostering a culture of scientific excellence and engagement across her teams.Prior to this role, Dr. He was VP and Head of the Material & Analytical Sciences Department at Boehringer Ingelheim, leading a large team of multidisciplinary scientists to develop and apply scientific methods and tools to support new drug development of chemical and biological entities. Dr. He has previously worked for several large pharmaceutical companies, including Pfizer, GSK, Pharmacia & Upjohn before joining Boehringer Ingelheim. She received her Pharmacy B.S. degree from Beijing Medical University, M.S. degree in Pharmaceutics from University of Minnesota, Ph.D. degree in Pharmaceutics from Purdue University and M.B.A. degree from Western Michigan University.Dr. He has also taught several short courses, given numerous podium presentations at national and international conferences, published many peer-reviewed papers and book chapters, and held several patents. She has been a member of scientific and editorial advisory boards for the Journal of Pharmaceutical Sciences since 2013.Dr. He has also been volunteering with organizations such as the United States Pharmacopeia (USP) since 2005, first with the Excipient Monograph Expert Committee (2005-2010), then with the General Chapter-Physical Analysis Expert Committee (2010-2015). She has served as the Chair of the General Chapters–Physical Analysis Expert Committee during the 2015–2020 cycle.Boehringer Ingelheim Open Innovation Portal - https://www.opnme.com/Support the Show.

Welcome to Episode 36 of “The 2 View,” the podcast for EM and urgent care nurse practitioners and physician assistants! Show Notes for Episode 36 of “The 2 View” – Marijuana as a schedule III drug, treating sunburns and other skin problems, pulse oximetry and racial bias, and diagnosing lower UTIs. Marijuana as a schedule III drug Burton KW. The DEA Plans to Reschedule Marijuana: What Happens Next? Medscape: Emergency Medicine. Published May 2, 2024. Accessed May 10, 2024. https://www.medscape.com/viewarticle/dea-plans-reschedule-marijuana-what-happens-next-2024a10008ka?ecd=wnledittpal_etid6489685&uac=106964SV&impID=6489685 Dea.gov. DEA: United States Drug Enforcement Administration. Accessed May 10, 2024. https://www.dea.gov/drug-information/drug-scheduling Treating sunburns and other skin problems 12 Summer Skin Problems You Can Prevent. Aad.org. American Academy of Dermatology Association. Accessed May 10, 2024. https://www.aad.org/public/everyday-care/skin-care-secrets/routine/prevent-summer-skin-problems Benedetti J. Sunburn. Merck Manual Professional Edition. Reviewed/Revised Oct 2023. Accessed May 10, 2024. https://www.merckmanuals.com/professional/dermatologic-disorders/reactions-to-sunlight/sunburn Faurschou A, Wulf HC. Topical corticosteroids in the treatment of acute sunburn: A randomized, double-blind clinical trial. Arch Dermatol. PubMed. NIH: National Library of Medicine: National Center for Biotechnology Information. Published May 2008. Accessed May 10, 2024. https://pubmed.ncbi.nlm.nih.gov/18490588/ How to Treat Sunburn. Aad.org. American Academy of Dermatology Association. Accessed May 10, 2024. https://www.aad.org/public/everyday-care/injured-skin/burns/treat-sunburn Skowrońska W, Bazylko A. The Potential of Medicinal Plants and Natural Products in the Treatment of Burns and Sunburn—A Review. Pharmaceutics. PMC: PubMed Central. NIH: National Library of Medicine: National Center for Biotechnology Information. Published February 2023. Accessed May 10, 2024. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958865/ Pulse oximetry and racial bias Gudelunas MK, Lipnick M, Hendrickson C, et al. Low Perfusion and Missed Diagnosis of Hypoxemia by Pulse Oximetry in Darkly Pigmented Skin: A Prospective Study. Anesth Analg. PubMed. NIH: National Library of Medicine: National Center for Biotechnology Information. Published March 1, 2024. Accessed May 10, 2024. https://pubmed.ncbi.nlm.nih.gov/38109495/ Valbuena VSM, Seelye S, Sjoding MW, et al. Racial bias and reproducibility in pulse oximetry among medical and surgical inpatients in general care in the Veterans Health Administration 2013-19: multicenter, retrospective cohort study. BMJ. Published July 6, 2022. Accessed May 10, 2024. https://www.bmj.com/content/378/bmj-2021-069775.long Diagnosing Lower UTIs Aydemir B, Overton D. Diagnosing Lower Urinary Tract Infections. ACEP Now: The Official Voice of Emergency Medicine. Published May 10, 2024. Accessed May 10, 2024. https://www.acepnow.com/article/diagnosing-lower-urinary-tract-infections/ Recurring Sources Center for Medical Education. Ccme.org. http://ccme.org The Proceduralist. Theproceduralist.org. http://www.theproceduralist.org The Procedural Pause. Emergency Medicine News. Lww.com. https://journals.lww.com/em-news/blog/theproceduralpause/pages/default.aspx The Skeptics Guide to Emergency Medicine. Thesgem.com. http://www.thesgem.com Trivia Question: Send answers to 2viewcast@gmail.com Be sure to keep tuning in for more great prizes and fun trivia questions! Once you hear the question, please email us your guesses at 2viewcast@gmail.com and tell us who you want to give a shout-out to. Be sure to listen in and see what we have to share!

Many health conditions require medicines that can be delivered to specific parts of the body. For instance, someone with asthma requires medication that targets the lungs, while someone with a neurodegenerative disease needs therapeutics that can penetrate the blood-brain barrier. But how do scientists create medicines that not only reach their intended targets but also produce the desired pharmacological effect while minimizing side effects and ensuring convenience for the patient? In this episode, co-host Danielle Mandikian chats with Karthik Nagapudi, Executive Director of Pharmaceutics, to explore the pivotal role of drug delivery strategies, highlighting how incorporating drug delivery considerations from the initial stages of drug development is crucial for creating next-generation medications. Read the full text transcript at www.gene.com/stories/no-delivery-no-drug

Purpose of these episode: These are not at all for medical advice or suggestions, we disclaim any loss in any way. These episodes are for educational purposes only, and are not for medical advice or suggestions. The views of this podcast represent those of my guest(s) and I. --- TNSPPE: Interview with Dean Beyah (Georgia Tech)| Pharmaceutics Discussions| Pharmacy Admissions Tips in English, French& Spanish -- Purpose of these episode: These are not at all for medical advice or suggestions, we disclaim any loss in any way. These episodes are for educational purposes only, and are not for medical advice or suggestions. The views of this podcast represent those of my guest(s) and I.

A client uses fentanyl patches to manage chronic pain from a back injury. What kind of risk does this present to the therapist? And, if we're not careful, the bigger risk might be to the client. Check it out on this episode of “I Have a Client Who . . .” with Ruth Werner. Resources:   Cai, B., Engqvist, H. and Bredenberg, S. (2015) ‘Development and evaluation of a tampering resistant transdermal fentanyl patch', International Journal of Pharmaceutics, 488(1), pp. 102–107. Available at: https://doi.org/10.1016/j.ijpharm.2015.04.061. Commissioner, O. of the (2023) ‘Accidental Exposures to Fentanyl Patches Continue to Be Deadly to Children', FDA [Preprint]. Available at: https://www.fda.gov/consumers/consumer-updates/accidental-exposures-fentanyl-patches-continue-be-deadly-children (Accessed: 4 April 2024). ‘Drug Overdoses - Data Details' (no date) Injury Facts. Available at: https://injuryfacts.nsc.org/home-and-community/safety-topics/drugoverdoses/data-details/ (Accessed: 4 April 2024). Duragesic Transdermal: Uses, Side Effects, Interactions, Pictures, Warnings & Dosing - WebMD (no date). Available at: https://www.webmd.com/drugs/2/drug-14008/duragesic-transdermal/details (Accessed: 4 April 2024). Ep 186 – Fentanyl Patches: “I Have a Client Who . . .” Pathology Conversations with Ruth Werner (2022) Associated Bodywork & Massage Professionals. Available at: https://www.abmp.com/podcasts/ep-186-fentanyl-patches-i-have-client-who-pathology-conversations-ruth-werner (Accessed: 4 April 2024). Equity--OS-OPAE--1600, O. of P.A. and (no date) Fentanyl Exposure in Public Places | Washington State Department of Health. Available at: https://doh.wa.gov/community-and-environment/opioids/fentanyl-exposure-public-places (Accessed: 4 April 2024). Fentanyl Facts (2024). Available at: https://www.cdc.gov/stopoverdose/fentanyl/index.html (Accessed: 4 April 2024). Khan, S. and Sharman, T. (2024) ‘Transdermal Medications', in StatPearls. Treasure Island (FL): StatPearls Publishing. Available at: http://www.ncbi.nlm.nih.gov/books/NBK556035/ (Accessed: 4 April 2024). Kim, T.S. et al. (2015) ‘Comparison of adhesion and dissolution of fentanyl patches: Fentadur® and Durogesic DTrans®', Journal of Pharmaceutical Investigation, 45(5), pp. 475–480. Available at: https://doi.org/10.1007/s40005-015-0195-y. Mann, B., News, A.P.-K.H. and Bebinger, M. (2023) ‘In 2023 fentanyl overdoses ravaged the U.S. and fueled a new culture war fight', NPR, 28 December. Available at: https://www.npr.org/2023/12/28/1220881380/overdose-fentanyl-drugs-addiction (Accessed: 4 April 2024). Overdose (no date) Drug Policy Alliance. Available at: https://drugpolicy.org/overdose/ (Accessed: 5 April 2024). Prausnitz, M.R. and Langer, R. (2008) ‘Transdermal drug delivery', Nature Biotechnology, 26(11), pp. 1261–1268. Available at: https://doi.org/10.1038/nbt.1504. Shearn, I.T. (2023) Fentanyl myth: Police cry overdose, facts prove otherwise, NJ Spotlight News. Available at: https://www.njspotlightnews.org/special-report/fentanyl-myth-police-cry-overdose-facts-prove-otherwise/ (Accessed: 5 April 2024). Using Skin Patch Medicines Safely (no date). Available at: https://www.poison.org/articles/using-skin-patch-medicines-safely (Accessed: 4 April 2024). Wong, W.F. et al. (2023) ‘Recent Advancement of Medical Patch for Transdermal Drug Delivery', Medicina, 59(4), p. 778. Available at: https://doi.org/10.3390/medicina59040778.   Host:   Ruth Werner is a former massage therapist, a writer, and an NCBTMB-approved continuing education provider. She wrote A Massage Therapist's Guide to Pathology, now in its seventh edition, which is used in massage schools worldwide. Werner is also a long-time Massage & Bodywork columnist, most notably of the Pathology Perspectives column. Werner is also ABMP's partner on Pocket Pathology, a web-based app and quick reference program that puts key information for nearly 200 common pathologies at your fingertips. Werner's books are available at www.booksofdiscovery.com. And more information about her is available at www.ruthwerner.com.        Sponsors:   Books of Discovery: www.booksofdiscovery.com     Anatomy Trains: www.anatomytrains.com    Elements Massage: www.elementsmassage.com/abmp   Earthlite: www.earthlite.com

In today's episode of The Fit Beaute Report, I am beyond thrilled to welcome a very special guest and dear friend, Dr. Gabriella Baki. Our collaboration dates back to our first cosmetic chemistry camp, where we worked together to keep young girls off the streets of Houston by introducing them to the wonders of science and beauty. Having Dr. Baki on the show today feels like a true full-circle moment. Dr. Baki is an associate professor at the University of Toledo College of Pharmacy and Pharmaceutical Sciences, where she serves as the program director and main instructor for the BS in Pharmaceutical Sciences Cosmetic Science and Formulation Design major - the first and most comprehensive undergraduate program in the United States focused exclusively on cosmetics and personal care products. With a background as a pharmacist and a PhD in Pharmaceutics from the University of Szeged, Hungary, Dr. Baki brings a unique perspective and deep expertise to her research, which focuses on topical delivery for active ingredients and cosmetic actives, sensory testing of creams and lotions, and sun protection factor and broad-spectrum boosting technologies. Throughout her career, Dr. Baki has made over 20 technical presentations, written over 45 publications, contributed to book chapters, and even authored her own book, "Introduction to Cosmetic Formulation and Technology," now in its second edition. In addition to her academic and research achievements, Dr. Baki is actively involved in the cosmetic science community, currently serving as chair of the Society of Cosmetic Chemists NextGen Advisory Committee in 2023. I am so excited to dive into this conversation with Dr. Baki, exploring her groundbreaking work and the future of cosmetic science. So, let's get started! Connect with Dr. Baki on Linkedin click the link below: https://www.linkedin.com/in/gabriella-baki-5890693b/

The New Student Pharmacist's Podcast Experience- A Pharm-Adventure in Pharmaceutics. -- In this episode, we discuss the fundamentals of pharmaceutics. Definitely, an episode worth listening to! --- Note: The views of this podcast represent those of my guest(s) and I. -- Note: Purpose of these episodes- not at all, for advice or medical suggestions. These are aimed to provide support for peer pharmacists in training in educational and intellectually stimulating ways. Again, these are not at all for medical advice, or for medical suggestions. Please see your local state and board-certified physician, PA or NP, and pharmacist for medical advice and suggestions. Music citation: Top Flow by Pixabay

Mankind Pharma's New Launch - https://upakarma.com/ Mankind Pharma को Social Media पे Follow कीजिए :- YouTube : https://www.youtube.com/channel/UCRnBT-DEKwKLkjIVe37Vu8Q Instagram : https://www.instagram.com/mankindpharmaltd Facebook : https://www.facebook.com/MankindPharmaIndia/ Twitter : https://twitter.com/Pharma_Mankind LinkedIn : https://in.linkedin.com/company/mankind-pharma-ltd Website : https://www.mankindpharma.com/ राजीव जुनेजा जी को LinkedIn पे Follow कीजिए - https://in.linkedin.com/in/rajeev-juneja-27882a24b BeerBiceps SkillHouse का Course Join करने के लिए यहाँ CLICK करें : https://bbsh.in/launch-yt Use my referral code OFF50 to get a 50% Discount on a standard membership subscription. Valid till 15th January 2024 Only. BeerBiceps SkillHouse को Social Media पर Follow करे :- YouTube : https://www.youtube.com/channel/UC2-Y36TqZ5MH6N1cWpmsBRQ Instagram : https://www.instagram.com/beerbiceps_skillhouse Website : https://bbsh.in/launch-yt For any other queries EMAIL: support@beerbicepsskillhouse.com In case of any payment-related issues, kindly write to support@tagmango.com

Dive into a transformative discussion on sustainability with Dr. Stefan Siemer, Head of Corporate Sustainability at Weleda AG and Weleda Group.Dr. Siemer brings a fresh perspective on resilience as an underpinning concept that stretches across societal layers and environmental considerations, redefining it as a cornerstone of true sustainability.We explore Weleda's innovative approach to KPIs, incorporating elements of passion and enjoyment as metrics. This episode takes you on a historical journey through Weleda's century-long commitment to sustainable practices, highlighting their Living Soil Camp and state-of-the-art sustainable Logistics Center.Further, gain an insider's view of Weleda's path to sustainability certification, its impact on company image, public perception, and risk management. Dr. Siemer offers invaluable insights on the competitive advantages of a sustainability-first approach and the pressing need for solid frameworks in this sphere.Join us to deepen your understanding of sustainability, from strategy to implementation, with top-down decisions and actionable solutions to global issues!The podcast is powered by the corporate sustainability platform NXT Boardroom. Follow our latest updates on LinkedIn. Thanks for listening,Your host Valentin Weidl

Today, we are joined by Dr. Michael Shafor,  PharmD, who serves as an Adjunct Professor to the Pharmaceutics department at Nova Southeastern Pharmacy School, specializing in sterile compounding.  Dr. Shafor talks through how Pharmacy students learn about the importance of handling hazardous drugs and educating future professionals. He also explains the significance of USP regulations and why they are so vital in the pharmaceutical field.  Lastly, Dr. Shafor shares his input on why the Closed System Transfer Device (CSTD) needs to keep evolving as new discoveries are made in healthcare.    

An estimated 3 million Americans use kratom products for recreational purposes, in self-treatment of opiate addiction, and to manage pain. Yet, our scientific understanding of its safety, efficacy, and potential for addiction is still poorly understood. With new data emerging each year, scientists are starting to gain a better picture of the full spectrum of risks and benefits of this SE Asian medicinal herb. Our guest this week, Dr. Christopher McCurdy, is an internationally recognized expert on kratom. Chris is a Professor of Medicinal Chemistry and Pharmaceutics at the University of Florida College of Pharmacy, where he also directs the UF Translational Drug Development Core. We address questions like: What is kratom? Where does it come from and how does its traditional use differ from the ways it is consumed in the USA? What are the major active compounds found in kratom and how much variation is there in different products? What are the side effects of chronic versus acute use of kratom? And are there any drugs you should avoid taking in combination with kratom? #kratom #MedicinalPlants #Pain #Addiction #tea #Herbs #HerbalSafety #Stimulant #Science #foodiepharmacology #ChristopherMcCurdy 

“It's really important to look at where your target is and what the toxicities are associated with hitting that target. Make sure you include that thinking when you're talking about bispecifics,” ONS member Rowena (Moe) Schwartz, PharmD, BCOP, professor of pharmacy practice at the James L. Winkle College of Pharmacy at the University of Cincinnati in Ohio, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a discussion about the use of bispecific monoclonal antibodies in hematologic cancers and solid tumors.   You can earn free NCPD contact hours after listening to this episode and completing the evaluation linked below.   Music Credit: “Fireflies and Stardust” by Kevin MacLeod  Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD), which may be applied to the treatment ILNA category, by listening to the full recording and completing an evaluation at myoutcomes.ons.org by September 1, 2025. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of NCPD by the American Nurses Credentialing Center's Commission on Accreditation.  Learning outcome: The learner will report an increase in knowledge related to bispecific monoclonal antibodies in hematologic cancers and solid tumors.  Episode Notes  Complete this evaluation for free NCPD.  ONS Voice drug reference sheets and FDA announcements about bispecific anticancer therapies  ONS resources for cytokine release syndrome  Oncology Nursing Podcast Episode 176: Oncologic Emergencies 101: Cytokine Release Syndrome  Clinical Journal of Oncology Nursing article: STAT: Cytokine Release Syndrome  Clinical Practice Resource  Clinical Practice Video  Huddle Card™  Cancer article: The BiTE (Bispecific T-Cell Engager) Platform: Development and Future Potential of a Targeted Immuno-Oncology Therapy Across Tumor Types  Pharmaceutics article: Bispecific Antibodies in Cancer Immunotherapy: A Novel Response to an Old Question  U.S. Food and Drug Administration label search for package inserts  To discuss the information in this episode with other oncology nurses, visit the ONS Communities.   To find resources for creating an ONS Podcast Club in your chapter or nursing community, visit the ONS Podcast Library.  To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org.  Highlights From Today's Episode  “When we talk about bispecifics, we need to really pay attention to both the target on the cancer and the target for T-cell engaging, because that impacts both efficacy but also toxicity.” TS 4:20  “If you really look deep into the clinical trials, often the patients that are receiving these agents in clinical trials have had more than the required three or four lines of treatment. They may have had five or more lines of treatment. So it's really important to kind of look at where it sits right now, knowing, of course, that that's an evolving target.” TS 7:13  “One of the things I think can be missed, at times, is the fact that you need to consider the toxicities associated with your target on the cancer cell.” TS 10:06  “In terms of mitigating risk, there's been two major ways that have been done. One is a step-up dose schedule, and so one of the key things I would say: If you're not familiar with an agent that you're going to be administering, it's really important to review the entire step-up scheme because it's different for each agent. In some cases, patients need to be admitted to the hospital for the entire step-up strategy. Other times it's just the first dose. So it's really important to look at that.” TS 11:58  “I think we're going to get to the point where our teaching strategy is going to have to be somewhat tailored to the agent we're giving. So, how the drug is given during the step-up, what the subsequent cycling is going to be, whether it's going to be a Q21-day cycle or a weekly dosing administration or every-two-week administration after a certain point. So, I think some understanding of what to expect going forward because these are drugs that are given continually in most situations and so it's important for people to know what to expect.” TS 14:25  “I think we're going to see bispecifics that perhaps engage other aspects of the immune system besides CD3. In fact, those are in clinical trials. And I do believe that we're going to see these more and more developed for cancers beyond the hematologic malignancies. There's a lot of work being done at looking at targets that we know are helpful targets in certain cancers. And I think we'll see more drugs approved beyond the myeloma and the lymphoma and the leukemia space.” TS 20:42 

ทำความรู้จักกับ วิตามินอี พร้อมรู้ถึงคุณประโยชน์มากมายของวิตามินอี อาหารที่อุดมไปด้วยของวิตามินอี และยีนที่เกี่ยวข้องกับวิตามินอี

Episode 51: In this episode, host Angie Gust talks about the benefits of ashwagandha and moringa. These are dietary supplements that could help heal ourselves and maybe even the planet. Ashwaganda is an herb and moringa is a tree.  They both have some amazing properties and can live in arid conditions so they may be good for climate change- taking in CO2 without needing much water. Turning to the environment, last May, the  United States hosted the Agriculture Innovation Mission to bring together partners to increase and accelerate investment in and support for agriculture and food systems innovation for climate action.  It highlighted opportunities for climate solutions and climate-smart agriculture and food systems innovation in the lead-up to COP28 which is in the United Arab Emirates in November this year. References Adjonyoh, Z. Mar 9, 2021. What is moringa? Everything you need to know about the superfood. Today. https://www.today.com/food/moringa-health-benefits-what-know-about-superfood-t210949 DeSouza,J Apr 20, 2023 Creating Fabric Materials out of Bacteria. Happy Eco News.https://happyeconews.com/creating-fabric-materials-out-of-bacteria/ Horn, L, Natalia Shakela, Marius K. Mutorwa, Erold Naomab, Habauka M. Kwaambwa. Moringa oleifera as a sustainable climate-smart solution to nutrition, disease prevention, and water treatment challenges: A review, Journal of Agriculture and Food Research, Volume 10, 2022, 100397, Mikulska, P et al.  Ashwagandha (Withania somnifera)—Current Research on the Health-Promoting Activities: A Narrative Review. Pharmaceutics 2023, 15(4), 1057; https://doi.org/10.3390/pharmaceutics15041057 Raguraman, VR, Subramaniam, JR. Withania somnifera Root exrtract increases telomerase activity I the human HeLa cell line. Adv. Biosci Biotechnol 2016; 7:199-204. Sharma R, Martins N. Telomeres, DNA Damage and Ageing: Potential Leads from Ayurvedic Rasayana (Anti-Ageing) Drugs. J Clin Med. 2020 Aug 6;9(8):2544. doi: 10.3390/jcm9082544. PMID: 32781627; PMCID: PMC7465058. Sierra Club. Toiyabe Chapter. 100 things you can do to save the planet.https://www.sierraclub.org/toiyabe/100-things-you-can-do-save-planet Stohs SJ, Hartman MJ. Review of the Safety and Efficacy of Moringa oleifera. Phytother Res. 2015 Jun;29(6):796-804. doi: 10.1002/ptr.5325. Epub 2015 Mar 24. PMID: 25808883; PMCID: PMC6680322. USDA May 10, 2023 Final Day of AIM for Climate Summit Announces Groundbreaking Initiatives on the Road to COP28. https://www.usda.gov/media/press-releases/2023/05/10/final-day-aim-climate-summit-announces-groundbreaking-initiatives      

Care to learn more about how you can never suffer from a hangover and how to feel energetic the whole day with a simple patch on your skin? I'm sure you've heard of nicotine patches. But do you know that you can also have patches with supplements and even drugs? Well, join us in this episode of the Super Entrepreneurs Podcast where our guest, Scott D. Clary explains his innovation that has the potential to change the game for pharmaceutics. Who Is Scott D. Clary? Scott is the host of the Success Story podcast, which is a Top 10 Business Podcast. He interviews inspirational people, mentors, and leaders. However, it's his OnMi Patch company that's truly fascinating in this episode. Care to learn more about how you can never suffer from a hangover and feel energetic the whole day? How is Scott D. Clary Super?   Scott D. Clary can learn anything he sets his mind on, and that's his superpower. Nothing is impossible once you learn how to get to it. People like Scott who have such a mindset are often inspirational leaders and pioneers who inspire everyone else to follow in their footsteps.   Shahid Durrani's Key Insight: Shahid Durrani's great conversation with Scott D. Clary was very fruitful in terms of brainstorming ideas and sharing valuable insight. You can learn a great deal about how to start a podcast from this episode.    Chapter Stamps:   00:00 Introductions: Moving from Canada (too cold) to Florida (too hot, but can't complain) 01:13 OnMI Patch: get your supplements through your skin (it's more potent) 06:17 A new innovation in pharma 08:47 The Hangover and Energy patches are the best-selling 10:56 Shahid's great business idea (sell hangover patches to nightclubs lol) 15:13 How to do entrepreneurship the right way? 17:52 The right personality type for a startup business 20:10 Having other side-hustles (podcasting for example) 25:00 Covid changed the game for podcasting 26:00 The thing that all podcasters share 29:00 Mindset=Foundation 32:40 Scott D. Clary's Superpower: Ability to learn anything with confidence 35:03 Final words: Lots of Gold   Pullout Quotes: "If you want to do something, you want to build anything, you have to love it for a while.” “There's something about podcasting (...) If you do in for the wrong reasons (...) you have to condition yourself to fall in love with it.”   Socials: OnMi Patch:https://onmipatch.com/ Buy OnMi Patches:   Success Story Podcast: https://podcasts.apple.com/us/podcast/success-story-with-scott-d-clary/id1484783544 Scott D. Clary: https://www.scottdclary.com/ YouTube: https://www.youtube.com/c/scottdclary Instagram: https://www.instagram.com/scottdclary/?hl=en LinkedIn: https://www.linkedin.com/in/scottdclary/  

Episode 125: Non-opioid Chronic Pain Management Dr. Axelsson and Jesse explain how to treat chronic pain without opioids. Written by Anika Soleyn, MS4, Ross University School of Medicine. Edited by Jesse Lamb, MS3, American University of the Caribbean; Hector Arreaza, MD; and Fiona Axelsson, MD.This is the Rio Bravo qWeek Podcast, your weekly dose of knowledge brought to you by the Rio Bravo Family Medicine Residency Program from Bakersfield, California, a UCLA-affiliated program sponsored by Clinica Sierra Vista, Let Us Be Your Healthcare Home. This podcast was created for educational purposes only. Visit your primary care provider for additional medical advice.Axelsson:Welcome to the first episode of 2023, Happy new year! Today is January 10, 2023.What is chronic pain?According to the International Association for the Study of Pain, chronic pain is nonstop or reoccurring pain that lasts more than 3 months or beyond the expected clinical course of illness. Chronic pain can adversely affect well-being and quality of life. We used to think of pain as a response to tissue damage, and as the tissue heals, the pain dissipates, but chronic pain is much more complex than that because there may be no evidence of tissue damage, yet the nociceptors keep sending signals to the brain that there is damage.There are 3 options for the management of chronic pain: non-pharmacologic, nonopioid pharmacological and opioid management. CDC recommends a combination of nonpharmacological and non-opioid management for chronic pain. The 7 most common chronic pain conditions are neuropathic pain, fibromyalgia or chronic pain syndrome, osteoarthritis, inflammatory arthritis, low back pain, chronic headache, and sickle cell anemia.Opioids in long-term care facilities.The use of opioids for the treatment of pain is common in the post-acute and long-term care setting. From the AFP Journal, the Choosing Wisely Recommendation states: “Don't provide long-term opioid therapy for chronic non-cancer pain in the absence of clear and documented benefits to functional status and quality of life.” The Society for Post-Acute and Long-Term Care Medicine published a statement in 2018 about the use of opioids. It states that the prescription of opioids should be based on an interprofessional assessment specifying why opioids are needed. When long-term opioids are not being used for cancer, palliative care, or end-of-life care in a long-term facility, a tapering plan must be “individualized and should minimize symptoms of opioid withdrawal while maximizing pain treatment with non-pharmacologic therapies and non-opioid medications”. Long-term opioid prescriptions should be reviewed regularly and take into consideration the potential harms of opioids. Clinicians are encouraged to offer alternatives such as behavioral therapy, non-opioid analgesics, and other non-pharmacologic treatments whenever available and appropriate.Initial assessment: Identify biopsychosocial factors and identify if the source is neuropathic, nociceptive, or central sensitization. This can be a challenging process and it may require several visits to determine the origin of pain. Neuropathic pain is due to nerve damage or irritation while nociceptive pain is due to tissue damage. Central sensitization is an abnormal response of the nociceptive system. There are changes in the nervous system that alter how it responds to sensory input that causes widespread pain with no apparent cause or in response to mild sensory input. Some examples include fibromyalgia, migraines in response to brushing hair, surgical scar pain, etc.Set goals and expectations: It is crucial to set up patient expectations if they have chronic pain. They should understand that pain can be improved to a manageable level but not always eliminated. Patients should have routine follow-up visits with education, and reassurance since they are shown to improve outcomes of pain management. Specific goals such as improved mobility and ability to do certain enjoyable tasks are more reasonable and specific goals than a goal of pain elimination. A good physician-patient relationship and clear communication are essential here. Patients could obviously become deeply upset at the prospect of pain that can't be eliminated, and those who have received opioids for their pain in the past could be even more distraught at the thought of not getting them now or needing to reduce their dose. The physician should be ready to have this discussion with their patients that have chronic pain and be ready to address their concerns appropriately. Reduce catastrophic thinking: Pain is an alarm system letting someone know there is some sort of damage. Because of this, it makes sense that a patient would respond to pain with anxious and catastrophic thinking. Patients who understand their own chronic diseases are more likely to be actively involved in their treatment, so understanding is crucial in the management of pain. Reducing fearful thoughts such as "there must be something wrong," and "hurt means harm'” is an important first step toward pain self-management and making sure the strategies attempted are effective.Rehabilitation: Focused pain clinics often include educational group classes for patients in distress. The programs include explanations for why pain might be present with no pathological factors. It also includes relaxation and mindfulness that help patients soothe themselves during attacks. The brain plays a big role in the experience of pain. Changing how your brain relates physical pain to stress and reducing those psychosocial barriers through self-care helps with pain management. Finding things that make you physically stronger like physical therapy or occupational therapy help, but also increasing mental strength by doing things that make you happy and having a quality social life is a strong determinant of how the brain perceives physical pain. Consistency is key in pain management even after the patient begins to feel better.Non-pharmacologic therapy – Most of what we will talk about today is non-pharmacological treatment. We will discuss the options and goals of different treatments. Chronic pain treatment should start with non-pharmacological approaches and then you can add medications if necessary. Again, these approaches aim to increase functionand reduce progression despite chronic pain. There should be a consistent non-pharmacological regimen, even if medications are added later. The three main approaches will be physical therapy, psychological therapy, and some integrative medicine methods.Physical therapy. The objective of physical therapy is to improve physical function. You should recommend programs that are specific for patients' limitations and the physical therapist should have trained specifically in chronic pain treatment. This ensures they do a proper initial evaluation and select appropriate therapeutic methods such as Therapeutic exercise: Sometimes patients can become so fearful of painful movement that they have deconditioned muscles. In the geriatric population, some patients are so afraid of falling, that they avoid any form of movement whatsoever, therefore almost certainly leading to falls due to deconditioning of those muscles. Adding small amounts of exercise as tolerated can begin to recondition patients and help them build strength. Patients with severe osteoarthritis are more likely to tolerate aquatic exercises. Therapeutic exercise programs may be available at the physical therapy facility or community centers. Patients can even find videos on the internet of tai chi, yoga classes, Pilates, and low-impact fitness programs. Exercise can certainly reduce pain and improve function, with few adverse effects but make sure patients tolerate the exercises and are not pushed beyond their limits. Stretching can also improve range of motion and strength, especially in chronic lower back pain patients. Psychological therapy:Cognitive-behavioral therapy. It is the most researched and recommended psychological treatment for chronic pain. It's normally recommended in conjunction with patient education, physical therapy, and exercise. CBT can be used after introducing meds and/or after surgery. There are 2 components to cognitive behavioral therapy: cognitions and behaviors. CBT addresses the way that patients' thoughts (cognitions) affect their actions and vice versa. This begins with helping patients identify situations and environments that trigger their pain and what they actually experience emotionally, behaviorally, and physically when they have pain.CBT addresses mental responses that may worsen pain, so patients learn to think about how they view their pain. To do this, they use a range of specific behavioral strategies such as relaxation and controlled-breathing exercises, activity pacing, pleasurable activities, improving their sleep, and cognitive reappraisal strategies, such as reframing negative situations to positive or practicing gratefulness.Complementary and integrative health therapies.-Mindfulness-based stress reduction. Mindfulness is the ability to be fully present where we are and what we're doing, and not be overly reactive or overwhelmed by what's going on around us.-Progressive muscle relaxation. For instance, tensing/relaxing muscles throughout the body along with positive imagery and meditation.-Biofeedback. During biofeedback, you're looking at biological signs, and feedback that is being correlated to physical sensations in your body to recognize the correlation between physical signs and symptoms of chronic pain. You're connected to monitors, such as electromyograms or electroencephalograms, to quantify muscle tension, brain waves, heart rate, and blood pressure to see how fluctuations and abnormal numbers physically feel in the body.-Massage therapy. It can relax painful muscles, tendons, and joints and relieve stress. The effect of pressure in certain areas that are tender causes relaxation and secretion of endorphins that can calm pains. That's why massage therapy can actually be addictive for some people, because of the endorphins. Another benefit of massage therapy is that it can help with improved absorption of medications due to improved circulation.There are many other integrative health therapies including Reiki, hypnosis, therapeutic touch, healing touch, and homeopathy. However, these are not well-researched and can't really be endorsed by evidence-based medicine.If patients are interested in trying complementary, integrative health therapy, you can guide them to practices that are at least safe. Some therapies can end up being harmful, such as herbal remedies or supplements with potential toxicities or known interactions with medications, so those should be taken cautiously. Make sure your med list while taking your history includes supplements and herbs patients might be trying. Shirodhara is an Ayurvedic approach to stress relief that involves having someone pour liquid — usually oil, milk, buttermilk, or water — onto your forehead.Herbal or plant-based treatments have also shown some efficacy in published studies. Ginger, turmeric, St John's Wort, and a handful of others seem like they could have some beneficial effects either on their own merit or as an adjunctive with other non-opioid therapies. Caution should be taken, though, as some of them, particularly St John's Wort, have been shown to have negative impacts on serum levels of opioids when used in combination with them due to their effects on the liver cytochrome system. Data is also rather mixed, with some studies showing reasonable efficacy and others showing almost none. If your patients want to take herbal supplements, it is essential to be diligent about checking their efficacy and interactions with other therapies to ensure safety. The physician should also be clear when discussing current medications to ask specifically if they take herbal supplements of any kind, as many patients don't consider these to be “medications” and will omit them during history. Of note, turmeric has to be taken with black pepper for better GI absorption.Weight reduction: A healthy diet and fitness are always recommended. Online guidelines are helpful on topics such as healthy fats, vegetables, avoiding refined sugar, and more. Obesity is a pro-inflammatory state, but it is important not to blame chronic pain problems solely on obesity since patients may still have pain after losing weight. Weight reduction can be a part of that plan, but we should not promise a cure for chronic pain after a patient reaches an ideal weight. Sleep disturbances: Ironically, sleep improves pain, but pain makes sleep more difficult. If patients complain of sleep disturbances, start with behavioral changes, including improved sleep hygiene (keep a regular sleep schedule, exercise regularly, don't use caffeine and caffeinated beverages, don't eat too late at night) and stimulus control (the bed should only be used for two things: sleep and sex, get out of bed if you can't sleep, wake up at the same time every day, and avoid bright screens before bedtime because they confuse your brain); cognitive behavioral therapy (deal with concerns or worries that may interfere with sleep). Treating sleep disturbance may have a positive effect on the treatment of chronic pain. Acupuncture: It involves the insertion of very thin needles through the skin at specific points on the body. Acupuncture is a key component of traditional Chinese medicine and can be considered in patients with chronic pain. There are significant difficulties in studying acupuncture, but randomized trials suggest that acupuncture and placebo may have similar efficacy, and both are superior to no treatment. Pharmacologic therapy – For patients with inadequate analgesia despite nonpharmacologic therapies, we add carefully selected multi-targeted pharmacological therapies based on the type of pain (i.e., nociceptive, neuropathic, central sensitization) For nociceptive pain, start with non-steroidal anti-inflammatory drugs (NSAIDs) while continuing non-pharmacologic treatments. If that doesn't work add a topical agent such as lidocaine, capsaicin, or topical NSAIDs. Consider opioid treatment if neither of those works. For neuropathic pain, start with antidepressants or antiepileptic drugs: tricyclic antidepressants, SNRIs, pregabalin, gabapentin, or carbamazepine in addition to non-pharmacologic therapy. If those medications do not provide relief of pain, then you can consider adding topical agents and then opioids after weighing the risk and benefits. Side effects can be viewed as harmful, but we can use them for our benefit.Opioids are reserved for people with moderate to severe pain who cannot function. Once you identify a treatment that works for the patient, follow-up visits should be continued to promote behavioral changes, monitor therapeutic response, and treat side effects. A pain contract should also be signed.Follow-up visits – Schedule follow-up visits to continue educating patients and their families and caregivers, to continue motivational interviewing, and to monitor improvement. Refer patients who are not making enough progress, such as not reaching goals of function and quality of life, to comprehensive pain programs that can use additional modalities such as injections.Bottom line: Non-pharmacologic options should be considered in the management of all patients with chronic pain. The main non-pharmacologic strategies include physical therapy, psychological therapy, and complementary and integrative therapy. Remember to treat sleep disturbances and obesity as part of your plan. Add pharmacologic agents such as NSAIDs, antidepressants, and anticonvulsants when non-pharmacologic therapies do not help the patient reach their goals. Consider opioids only in moderate to severe pain with loss of function. Opioid prescription is a complex topic that was addressed in episode 31 of this podcast, more than 2 years ago, it is time for an update. Stay tuned, we will talk about opioids soon.____________________________Conclusion: Now we conclude episode number 125, “Non-opioid Chronic Pain Management.” Non-pharmacologic therapy is proven to be effective in the treatment of chronic pain, especially physical therapy, psychological therapy, and some complementary therapy. Medications can be added to non-pharmacologic therapy, mainly NSAIDs, antidepressants, antiepileptic medications, and more. Opioids can be added in disabling chronic pain, but prescription needs to be done cautiously and watchfully. The treatment of chronic pain may be challenging and daunting at times, but fortunately, we have science to back us up with effective ways to help our patients. So, don't be discouraged and trust science! This week we thank Fiona Axelsson, Jesse Lamb, and Hector Arreaza. Audio editing by Adrianne Silva.Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week! _____________________Links:Tauben, David, Brett R Stacey, Approach to the management of chronic non-cancer pain in adults, UpToDate. Last updated on May 06, 2022. Accessed January 10, 2023. https://www.uptodate.com/contents/approach-to-the-management-of-chronic-non-cancer-pain-in-adults.Choosing Wisely Recommendations: Don't provide long-term opioid therapy for chronic non-cancer pain in the absence of clear and documented benefits to functional status and quality of life, American Family Physician, Collections 460, American Academy of Family Physician. Link: https://www.aafp.org/pubs/afp/collections/choosing-wisely/460.html.What is Mindfulness? Mindful.org. https://www.mindful.org/what-is-mindfulness/.Jahromi B, Pirvulescu I, Candido KD, Knezevic NN. Herbal Medicine for Pain Management: Efficacy and Drug Interactions. Pharmaceutics. 2021; 13(2):251. https://doi.org/10.3390/pharmaceutics13020251.Royalty-free music used for this episode: “Good Vibes - Fashionista." Downloaded on October 13, 2022, from https://www.videvo.net/

In episode 14 we discuss the connection between early life trauma, depression, anxiety, stress, and opioid use disorder.Effects of Early Life Trauma on Risks for Adult Opioid Use Disorder Are Mediated by Stress and Occur Independent of Depression and Anxiety. Dunn, Kelly E. PhD, MBA; Turner, Gavin M. BS; Oswald, Lynn M. PhD.  Journal of Addiction Medicine: 11/12 2022 - Volume 16 - Issue 6 - p 709-715 doi: 10.1097/ADM.0000000000001011We also discuss an opinion piece on AMA discharges and the new fentanyl vaccine.Retiring the “Against Medical Advice” Discharge Robert A. Kleinman, Thomas D. Brothers, Nathaniel P. Morris. Ann Intern Med.2022;175:1761-1762. [Epub 29 November 2022]. doi:10.7326/M22-2964An Immunconjugate Vaccine Alters Distribution and Reduces the Antinociceptive, Behavioral and Physiological Effects of Fentanyl in Male and Female Rats Haile CN, Baker MD, Sanchez SA, Lopez Arteaga CA, Duddupudi AL, Cuny GD, Norton EB, Kosten TR, Kosten TA. Pharmaceutics. 2022; 14(11):2290. ---------Episode 14 Credits:Original theme music: composed and performed by Benjamin KennedyAudio production: Angela OhlfestVideo production: Paul Kennedy----------This is Addiction Medicine Journal Club with Dr. Sonya Del Tredici and Dr. John Keenan. We practice addiction medicine and primary care, and we believe that addiction is a disease that can be treated. This podcast reviews current articles to help you stay up to date with research that you can use in your addiction medicine practice. The best part of any journal club is the conversation. Send us your comments on Twitter, Facebook, YouTube, email, or join our Facebook group. Email: addictionmedicinejournalclub@gmail.com Twitter: @AddictionMedJC Facebook: @AddictionMedJC Facebook Group: Addiction Medicine Journal Club YouTube: addictionmedicinejournalclub Addiction Medicine Journal Club is intended for educational purposes only and should not be considered medical advice. The views expressed here are our own and do not necessarily reflect those of our employers or the authors of the articles we review. All patient information has been modified to protect their identities.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Sarah Stevens, SVP and Head of Early Development & Late Stage Commercial Operations at Quotient Sciences.   Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sarah, covering:   Carving an incredible transatlantic CDMO career in traditionally non-female roles - balancing work, kids and breast cancer. Words of wisdom for young women developing a career in the outsourcing space, including an appreciation of valuing the female perspective. The concept of Translational Pharmaceutics® - delivering an agile and integrated offering for accelerating to first-in-human (FIH) clinical trials and optimizing dosage forms for proof-of-concept and beyond. Potential impact of uncontrollable macro factors and current industry trends on demand for contract services and volunteer recruitment   Sarah is the Senior Vice President & Head of Early Development & Late Stage Commercial at Quotient Sciences, with oversight for all global sites and operational functions from early drug development programs through to late stage and commercial manufacturing. Sarah oversees deployment of Quotient's unique platform for integration, Translational Pharmaceutics, which eliminates white space between these traditionally silo'd drug development areas. Prior to this role, she was the Vice President of Drug Development Sciences, with responsibility for drug development consulting and creation of integrated programs across the organization.   Located in Boston, MA, Sarah's experience spans a range of scientific and leadership roles within the drug product contract development and manufacturing space. Sarah received her PhD in Pharmaceutics from the University of Manchester and her MPharm, Pharmacy from Strathclyde University.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Sarah Stevens, SVP and Head of Early Development & Late Stage Commercial Operations at Quotient Sciences. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Sarah, covering: Carving an incredible transatlantic CDMO career in traditionally non-female roles - balancing work, kids and breast cancer. Words of wisdom for young women developing a career in the outsourcing space, including an appreciation of valuing the female perspective. The concept of Translational Pharmaceutics® - delivering an agile and integrated offering for accelerating to first-in-human (FIH) clinical trials and optimizing dosage forms for proof-of-concept and beyond. Potential impact of uncontrollable macro factors and current industry trends on demand for contract services and volunteer recruitment Sarah is the Senior Vice President & Head of Early Development & Late Stage Commercial at Quotient Sciences, with oversight for all global sites and operational functions from early drug development programs through to late stage and commercial manufacturing. Sarah oversees deployment of Quotient's unique platform for integration, Translational Pharmaceutics, which eliminates white space between these traditionally silo'd drug development areas. Prior to this role, she was the Vice President of Drug Development Sciences, with responsibility for drug development consulting and creation of integrated programs across the organization. Located in Boston, MA, Sarah's experience spans a range of scientific and leadership roles within the drug product contract development and manufacturing space. Sarah received her PhD in Pharmaceutics from the University of Manchester and her MPharm, Pharmacy from Strathclyde University. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is sponsored and funded by ramarketing. An international content, design and digital agency that helps companies in life sciences, get noticed.

Inspiring Stories 013 - Bahijja Raimi-Abraham

In this episode, we “deep dive” into diltiazem, describing its most important drug facts, pharmacology and medicinal chemistry, pharmaceutics, AB compatibility, and important medication safety issues. Key Concepts Diltiazem is a non-dihydropyridine calcium channel blocker (CCB). This type of CCB reduces both heart rate and blood pressure whereas dihydropyridine CCBs only reduce blood pressure. Diltiazem has numerous dosage forms (IV, immediate release tablets, and extended-release products). Extended-release products are always dosed once or twice daily. Historically there were a significant number of extended-release capsules with a variety of brand names and AB-compatibility. Today, only a few branded products still exist in the US market (Cardizem CD, Cartia XT, Cardizem LA, Tiazac, Taztia XT). The FDA Orange Book describes “AB” compatibility, which outlines whether one formulation is therapeutically equivalent to another formulation. Depending on state law, pharmacists can use AB compatibility codes to automatically substitute formulations without notifying the prescriber. The numerous dosage forms of diltiazem is a medication safety issue. Remember that immediate release diltiazem is always dosed TID/QID (3-4 times per day) whereas extended-release formulations are always dosed once daily. A twice-daily extended-release product was previously on the market but has since been discontinued.

ONTARIO FOURTH DOSES AND STUDY ON OMICRON Libby Znaimer is joined by Dr. Barry Pakes, Medical Officer of Health for York Region, and Dr. Shawn Owen, Associate Professor in the department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah. Today: the province is expanding fourth dose eligibility to adults 18 years of age and older. Meanwhile, a new study out of the University of Toronto reveals that individuals who were infected by the COVID-19 virus before 2022 have little protection against Omicron. Our health experts weigh in on the latest news. PATRICK BROWN AND BRAMPTON CITY COUNCIL Libby Znaimer is joined by John Mykytyshyn, Patrick Brown's campaign manager, and Bob Richardson, liberal strategist and Senior council to National Public Relations. Patrick Brown was disqualified last week from the Conservative Party leadership race over allegations his campaign broke financing rules. Yesterday, we learned that his campaign co-chair has moved to join the Jean Charest campaign team. And, Patrick Brown, has also indicated that he will endorse Charest should he not have enough time to fight to re-include himself in the race. Meanwhile, an Ontario Superior Court justice has overturned the controversial appointment of a Brampton City Councillor. BANK OF CANADA HIKES KEY RATE BY 1 PERCENTAGE POINT: WHAT THAT MEANS FOR YOU Libby Znaimer is joined by Allan Small, Senior Investment Advisor with Allan Small Financial Group IA Private Wealth and Gordon Pape, Editor and Publisher of the Internet Wealth Builder and Income Investor newsletters. The Bank of Canada has raised the key rate by one full percentage point. What that means for you.

Wound Healing Accelerated with Topical DIM The phytochemical 3,3'-diindolylmethane (DIM) successfully broke down the biofilms protecting two different pathogens including Acinetobacter baumannii and pseudomonas aeruginosa– enabling their eradication 65% and 70% of the time, respectively. Combined with antibiotics, that number jumped to 94%. Golberg K, Markus V, Kagan B-e, Barzanizan S, Yaniv K, Teralı K, Kramarsky-Winter E, Marks RS, Kushmaro A. Anti-Virulence Activity of 3,3′-Diindolylmethane (DIM): A Bioactive Cruciferous Phytochemical with Accelerated Wound Healing Benefits. Pharmaceutics. 2022; 14(5):967. https://doi.org/10.3390/pharmaceutics14050967 #DIM #wounds #healing #ulcers DIM, Wounds, Healing, ULCERS, BIOFILM, P. aeruginosa , Pseudomonas aeruginosa, Gram-negative pathogens, Phytochemicals, Antimicrobial , Acinetobacter baumannii, hospital infections, battlefield infections, A. baumannii, Diindolylmethane, acne, candida --- Support this podcast: https://anchor.fm/ralph-turchiano/support

Wound Healing Accelerated with Topical DIM The phytochemical 3,3'-diindolylmethane (DIM) successfully broke down the biofilms protecting two different pathogens including Acinetobacter baumannii and pseudomonas aeruginosa– enabling their eradication 65% and 70% of the time, respectively. Combined with antibiotics, that number jumped to 94%. Golberg K, Markus V, Kagan B-e, Barzanizan S, Yaniv K, Teralı K, Kramarsky-Winter E, Marks RS, Kushmaro A. Anti-Virulence Activity of 3,3′-Diindolylmethane (DIM): A Bioactive Cruciferous Phytochemical with Accelerated Wound Healing Benefits. Pharmaceutics. 2022; 14(5):967. https://doi.org/10.3390/pharmaceutics14050967 #DIM #wounds #healing #ulcers DIM, Wounds, Healing, ULCERS, BIOFILM, P. aeruginosa , Pseudomonas aeruginosa, Gram-negative pathogens, Phytochemicals, Antimicrobial , Acinetobacter baumannii, hospital infections, battlefield infections, A. baumannii, Diindolylmethane, acne, candida DIM, Wounds, Healing, ULCERS, BIOFILM, P. aeruginosa , Pseudomonas aeruginosa, Gram-negative pathogens, Phytochemicals, Antimicrobial , Acinetobacter baumannii, hospital infections, battlefield infections, A. baumannii, Diindolylmethane, acne, candida --- Support this podcast: https://anchor.fm/ralph-turchiano/support

How far is the Pharmaceutical 3D Printing Revolution? In this episode, Simon speaks with Professor Mo Maniruzzaman, Assistant Professor in Pharmaceutics and Drug Delivery Assistant Professor in Pharmaceutics and Drug Delivery, The University of Texas at Austin. They speak about: How he became passionate about 3D printing How far are we from personalized medicine through 3D printing? How will Personalized “Pill Printing” evolve as the industry grows

[Dr.Amp Podcast ตอนพิเศษ] เคล็ด(ไม่)ลับ เพื่อสุขภาพดีของหมอแอมป์ EP.3 เรื่อง การดูแลผิวพรรณของหมอแอมป์

Videos: 1. Matt Taibbi – Shouldn't Hillary Clinton Be Banned From Twitter Now? (Read) 2. Parents Talking To The School Board, About Filth in Schoolbooks (4:55) 3. Journalist Dr Udo Ulfkotte was paid to spread propaganda and push for war with Russia! (13:22) 4. Eugenics and America's Campaign to Create a Master Race: War Against the Weak (2003) (Start at 3:00, Play For 15 mins) 5. World Economic Forum – Hackable Humans – Yuval Noah Harari, 6. Bill Gates – ” We didn't understand that it's a fairly low fatality rate” Vitamin D may restore the body's natural barrier against ovarian cancer Nagoya University (Japan) Ovarian cancer has one of the highest death rates of all cancers. One reason for this is that the cancer turns the body's defenses against itself. However, new research from Nagoya University published in Matrix Biology suggests that vitamin D can effectively prevent one of the key pathways used by this cancer. Ovarian cancer often undergoes a process called peritoneal metastasis. In this process, its cells detach from their primary site in the ovary and travel to a secondary implantation site, such as the peritoneal wall or diaphragm. The peritoneum defends against this process using a barrier consisting of mesothelial cells, which prevent the adhesion of cancer cells and limit their spread. However, ovarian cancer gets around this defense by transforming the protective mesothelial cells into cancer-associated mesothelial cells. This creates an environment that helps metastasis, assisting the spread of cancer around the body. (Next) Herbal supplement shows promise against lung cancer University of Technology at Sydney Berberine, a natural compound found in plants such as barberry and goldenseal, suppresses the proliferation of lung cancer cells in the lab, new research shows. It also reduces airway inflammation and damage to healthy lung cells exposed to chemicals from cigarette smoke. The evaluation of berberine's effect on non-small cell lung cancer has just been published in the journal Pharmaceutics. It shows that berberine exhibits potent anticancer activity, suppressing cancer cell growth in vitro. The study follows research recently published in Antioxidants, also led by Dr. Dua, showing berberine can inhibit oxidative stress, and reduce inflammation and cellular senescence induced by cigarette smoke extract in lab-grown human healthy lung cells. (Next) N-acetylcysteine could improve concussion recovery Midwestern University (Arizona) A study reported on April 8, 2022, in The Journal of Trauma and Acute Care Surgery revealed improvement in symptoms of concussion among older men and women with mild traumatic brain injury (TBI) who received supplements containing the antioxidant amino acid N-acetylcysteine (NAC). Free radicals produced following brain injury react with lipids to create toxic molecules within the first hours following a traumatic brain injury. Dr McPherson and his associates suggested that the damage caused by these molecules could be responsible for the symptoms that occur after a concussion and that the use of compounds such as NAC could help mitigate some of these symptoms. The study included 65 traumatic brain injury patients of an average age of 76 years who were within three hours of trauma surgery service evaluation. Thirty-four patients received standard treatments for TBI plus 4 grams NAC within three hours of injury, followed by a 3-day period during which 2 grams NAC was administered twice per day and an additional 3 days during which 1.5 grams NAC was provided twice daily. The remainder of the participants received standard treatment alone. Questionnaires that evaluated post-concussion symptoms were administered at the beginning of the study and at 7 and 30 days. Questionnaire scores were significantly better in the NAC group on days 7 and 30. (Next) Ozone antiseptic shows potential for treating severe gum infections Research SEA (Japan) A powerful new antiseptic agent, called ozone nanobubble water, holds promise for the treatment of periodontitis, or severe gum infections, according to research published in the journal Science and Technology of Advanced Materials. The study, by Professor Shinichi Arakawa and colleagues, evaluated the bactericidal activities of ozone nano-bubble water — also known as NBW3 — against the two main bacterial agents that cause periodontitis. It also assessed NBW3's toxicity to human oral tissue cells. Their results showed that NBW3 can kill periodontal pathogens within 30 seconds of exposure, yet has only a minor impact on the viability of oral tissue cells after 24 hours of exposure. Based on their in vitro results, the researchers conclude that NBW3 could become a valuable tool for treating periodontitis. (Next) Eating a Mediterranean diet could cut womb cancer risk Institute of Pharmacological Research (Italy) Women who eat a Mediterranean diet could cut their risk of womb cancer by more than half (57 per cent), according to a study published in the British Journal of Cancer*. The Italian researchers looked at the diets of over 5,000 Italian women to see how closely they stuck to a Mediterranean diet and whether they went on to develop womb cancer**. The team broke the Mediterranean diet down into nine different components and measured how closely women stuck to them. The diet includes eating lots of vegetables, fruits and nuts, pulses, cereals and potatoes, fish, monounsaturated fats but little meat, milk and other dairy products and moderate alcohol intake. Researchers found that women who adhered to the Mediterranean diet most closely by eating between seven and nine of the beneficial food groups lowered their risk of womb cancer by more than half (57 per cent). Those who stuck to six elements of the diet's components reduced their risk of womb cancer by 46 per cent and those who stuck to five reduced their risk by a third (34 per cent). But those women whose diet included fewer than five of the components did not lower their risk of womb cancer significantly.

It's Monday and that means it's time for a new episode of YB's Collaboration Corner! If you desire to share your story with the world, want to advance  in your career, create conversations and connections, and don't want to take years to do it  then this is for you. This week join President of Sales Rob "YB" Youngblood for conversation & connection with Dr. Susanna Wu-Pong Calvert, Founder and Executive Director of the Foundation for Family and Community Healing.Dr. Susanna Wu-Pong Calvert is a 26-year veteran of higher education, first starting at Virginia Commonwealth University where she was a faculty member in the School of Pharmacy, Department of Pharmaceutics, and Director of the Pharmaceutical Sciences Graduate Program for 11 years.  She joined the Office of Faculty Affairs at the University of Georgia in 2016 as the inaugural Director of Programming, where she supported faculty success and wellbeing, and leadership and organizational development for the 2300 faculty across the UGA campuses.  In 2018, she founded the Foundation for Family and Community Healing (www.HealingEdu.org), which focuses on creating vibrant connections between individuals and their families, communities, and with Earth to promote wellbeing for all.  Susanna has a Bachelors Degree in Pharmacy from the University of Texas, Austin, a Masters of Applied Positive Psychology from the University of Pennsylvania, a PhD in pharmacy and pharmaceutical chemistry from the University of California, San Francisco and a postdoctoral fellowship in dermatology, also at UCSF.  During her career she has published almost 100 journal articles, books, and book chapters, and has written hundreds of blogs for the Silver Lining blog (www.findingpositiveperspective.wordpress.com) and through FFCH.   She has several coaching credentials including Clifton StrengthsFinders, Growth Edge Coaching, Arbinger Institute, and the Leadership Circle, and is trained as a life coach.  Her passion is in helping individuals and organizations find and pursue their calling and the highest versions of themselves.    Reach out to Dr. Calvert:http://www.healingedu.org/For Speaking & Consulting she may be reached here:http://www.susannacalvert.org/Tune in for a new episode every Monday night at 7:00 pm (CST). Just choose "YB's Collaboration Corner Podcast" when you click the magic link below!https://linktr.ee/selfpublishn30daysYou can also watch this episode on our YouTube channel!https://youtu.be/ssd4R-VWhfEDon't forget to subscribe to our podcasts on iTunes, Spotify or Stitcher so you won't miss an episode!If you have been thinking about how to publish a book but you're not sure how, Self Publish -N- 30 Days is the company for you! As the #1 Self Publishing Company in the world we are able to publish your book faster and with less stress than other services. We offer the same services as KDP Amazon  but with a personalized approach. We know that to publish on Amazon, there are several steps that seem intimidating if you don't know what to do. At Self Publish -N- 30 Days our skilled team will walk you through the whole process of how to write a book step by step. Contact Us Today!This Is The Year For Your New Book!

What can you incorporate in your medical sales business to boost performance? In this episode, you will learn all about a game-changing software that does just that. Its creator, Justin Lohman shares his career journey as a salesperson, where he gained a lot of experience and realized that you always need to have a plan. So, from selling, he shifted to management, training other people. Through the process, he learned that most people are asking and looking for technology to help them with their tasks, so he created Rithm AI. It is a sales technology that assists you with planning, organizing, routing, and prospecting, allowing salespeople to maximize their time. Find out more by tuning in! Love the show? Subscribe, rate, review, and share! Here's How » Join the Medical Sales Podcast Community today: evolveyoursuccess.com

In this episode, we interview Dr. Danyelle Martin, a Medical Science Liaison (MSL) at Moderna, in order to learn more about the what, how, and future of mRNA-based therapeutics, and what impact it can have on healthcare and healthcare professionals in general. Key Concepts Moderna has a “Research Engine” proprietary service that takes an mRNA idea from a web-based digital designer, to a digital ordering system, and finally to a production facility where mRNA constructs are synthesized and quality tested. Pharmaceutics play a big role in the formulation of mRNA particles. Lipid nanoparticles (LNPs) play an important role for stability and delivery of mRNA cargo. After LNPs and mRNA are co-formulated, the product is purified, filtered, frozen, and subjected to a series of good manufacturing practice (GMP) tests to ensure product quality. COVID-19 vaccines are a small glimpse into the potential future of mRNA-based therapeutics. Moderna's pipeline includes mRNA vaccines for other viruses (including RSV, influenza, Zika and CMV) as well as therapeutics for non-viral diseases (including a personalized cancer vaccine and a VEGF-A mRNA molecule for myocardial ischemia).

Life is a journey, right? Trust the process, ok? Resilience is everything, apparently. This week we talk about why the current self-help buzzwords make us feel like we're failing. So we decide to add injury to insult and set a series of challenges for grown-ups - introducing Squidult Games. We also discuss why we are constantly vacillating between frenzied hyperworkmode and a near-catatonic state of existential dread and avoidance. Oh, and we interview the delightful Simon Gaisford, Professor of Pharmaceutics at UCL about bacteria and why we need to look after our gut - so that it will look after us.  This podcast was bravely brought to you by Symprove - the water-based supplement that carries live and active bacteria to your gut in order to start to multiply and produce food for the bugs we already have. Be gut to yourself…You can sign up for a 12-week introductory programme – and here's your code for 15% discount: MIDULT15 at symprove.com.   Learn more about your ad choices. Visit megaphone.fm/adchoices

Report in the International Journal of Pharmaceutics details study results on Just Thrive Prebiotic/Probiotic combination to be more powerful when used together than separately.

In this episode, we discuss the fascinating science of pharmaceutics with Dr. Kristen Ahlschwede and Dr. Rahul Deshmukh. We explore how dosage forms and excipients play an important role in how a drug product behaves in the human body with a particular focus on fentanyl patches, osmotic tablets (with laser-drilled holes), Depakote Sprinkles, and IV amiodarone. Key Concepts Fentanyl patches were reformulated from a drug-in-a-reservoir system to an adhesive matrix system to prevent abuse and misuse. The new formulation prevents fentanyl from "leaking" out when cut. Osmotic tablet systems, such as Procardia XL, Glucotrol XL, and Concerta, use an "active" layer (containing drug) adjacent to a "push" layer that is osmotically active. When the push layer is exposed to water in the GI tract, it swells and pushes the active layer through a small laser-drilled precision hole. "Sprinkle" dosage forms typically involve small pellets inside a capsule, such as Depakote Sprinkles. The capsule itself does not delay or extend release; instead, the pellets themselves are involved in prolonging the absorption profile of the drug. Amiodarone IV is commercially available in two formulations -- the conventional formulation (Cordarone) contains benzyl alcohol and tween 80 to solubilize the drug but these excipients are associated with hypotension. A newer formulation (Nexterone) uses cyclodextrin as a solubilizing agent and is not associated with hypotension (although has a risk of nephrotoxicity, especially at higher cumulative doses).

Leading diverse progressive Judaism around the globe. Born in Buenos Aires in 1962, Rabbi Bergman holds a Bachelor's degree in Biochemistry and Pharmaceutics from the University of Buenos Aires, and three Master's degrees: in Education from The Hebrew University, in Hebrew Letters from Hebrew Union College – Jewish Institute of Religion, Jerusalem, and in Jewish Studies from the Jewish Theological Seminary, Jerusalem. He was ordained at the Latin American Rabbinical Seminary of Buenos Aires in 1992, and HUC-JIR in Jerusalem in 1993. He is a member of the Central Conference of American Rabbi (CCAR) and a graduate of the Jewish Agency's Jerusalem Fellows program. Founder of the Arlene Fern Community School in Buenos Aires, Rabbi Bergman is well-known for his innovative and inspirational socio-educational and religious projects with Fundación Judaica. He serves as Rabbi at Templo Libertad, Argentina's first Synagogue. Rabbi Bergman began his career as a community leader at Emanu El, epicenter of Argentina's Reform Movement. In 2011, he became the first rabbi ever elected to public office in Argentina and served as representative of the City of Buenos Aires. In 2013, he was elected to represent the city at the nation's congress and in 2015, President Mauricio Macri named him Minister of the Environment and Sustainable Development, a position he held until the end of President Macri's term in 2019. Named one of the world's 100 most influential leaders in the fight against climate change, Rabbi Bergman has received numerous international distinctions and awards. He has authored seven books, is a distinguished speaker on issues of social justice and human rights, and a strong exponent of civil discourse. Rabbi Bergman is honored to have been appointed President of the World Union for Progressive Judaism, beginning in June, 2020. He is married and has four children.

EGP Committee Member Mélanie Vogel is in conversation with Gaëlle Krikorian, a researcher and activist on public health. They discuss the fault lines of our healthcare system, and the role of patents play in the issue of unequal access to pharmaceutical goods and treatment.

Looking for a phlebotomy course in Brampton, ON? The Canadian College of Healthcare & Pharmaceutics offers a one-day practical workshop for nurses, lab technicians, and medical students. Learn more at https://cchap.ca (https://cchap.ca)

This week, Stacey is joined by Paul Pluta and Karen Zimm to discuss the particulars of the drug naming process, definitions, and categories for drug names. Karen and Paul present case study scenarios where drug name communications have led to adverse events.  A drug may be known by different names during its development and commercial lifecycle. Medication safety problems associated with drug names have long been recognized as a significant problem by healthcare professionals. Whether it's look alike or sound alike errors, drug modifier misidentification, or proprietary vs. non-proprietary names, confusion may lead to medication errors – which of course can have fatal effects on patients and consumers. Resources for this Episode: Articles: Medication Safety: Industry Considerations Part 1 - Problem Overview https://www.ivtnetwork.com/article/medication-safety-industry-considerations-part-1-problem-overview  Regulatory 101: Medication Safety - Industry Considerations, Part 2, Drug Names https://www.ivtnetwork.com/article/regulatory-101-medication-safety-industry-considerations-part-2-drug-names Regulatory 101: Drug Name Modifiers – Definition, Categories, Generics, And CAPA https://www.ivtnetwork.com/article/regulatory-101-drug-name-modifiers-%E2%80%93-definition-categories-generics-and-capa Regulatory 101: Biologic Non-Proprietary Drug Names – Terminology And Format https://www.ivtnetwork.com/article/regulatory-101-biologic-non-proprietary-drug-names-%E2%80%93-terminology-and-format  Medication Safety And Drug Names - Valproic Acid Product Problems https://www.ivtnetwork.com/article/medication-safety-and-drug-names-valproic-acid-product-problems References: FDA.  Guidance for Industry.  Best Practices in Developing Proprietary Names for Drugs. https://www.fda.gov/media/88496/download  FDA.  Contents of a Complete Submission for the Evaluation of Proprietary Names.  https://www.fda.gov/media/72144/download  FDA.  Safety Considerations for Product Design to Minimize Medication Errors.  https://www.fda.gov/media/84903/download  FDA. Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors.  https://www.fda.gov/media/85879/download  Medicines & Healthcare products Regulatory Agency (UK MHRA).  MHRA Guideline for the Naming of Medicinal Products and Braille Requirements for Name on Label. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/810914/MHRA_Guideline_for_the_Naming_of_Medicinal_Products_and_Braille_Requirements_for_Name_on_Label.pdf.%C2%A0 European Medicines Agency (EMA).  Guideline on the acceptability of names for human medicinal products processed through the centralized  procedure. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-acceptability-names-human-medicinal-products-processed-through-centralised-procedure_en.pdf. Health Canada.  Guidance Document for Industry.  Review of Drug Brand Names.  https://www.canada.ca/en/health-canada/services/drugs-health-products/reports-publications/medeffect-canada/guidance-document-industry-review-drug-brand-names.html Health Product Regulatory Authority (Ireland).  Guide to Invented Names of Human Medicines.  file:///D:/HPRA%20Drug%20names.pdf.  To Err is Human:  Building a Safer Health System.  Institute of Medicine, National Academic Press, Washington, DC, 2000.  https://www.ncbi.nlm.nih.gov/books/NBK225182  Preventing Medication Errors.  Institute of Medicine.  National Academic Press., Washington, DC, 2007. https://www.nap.edu/catalog/11623/preventing-medication-errors  Karen R. Zimm, Ph.D.  Karen is currently an Associate Director in Global Regulatory Affairs for Johnson & Johnson Pharmaceutical Research and Development with responsibility for Chemistry Manufacturing & Controls for API's and marketed products. Previously she has held positions in technical operations with Pharmaceutical Sourcing Group – Americas, a division of Ortho-McNeil Pharmaceutical and research & development for the R.W. Johnson Pharmaceutical Research Institute and Whitehall Robins Healthcare (Wyeth Consumer Products). She earned her Bachelor of Science in Pharmacy and PhD in Pharmaceutics under Dr Joseph Schwartz from the Philadelphia College of Pharmacy and Science, MBA in Pharmaceutical Management from Drexel University, and the MS in Quality Assurance/Regulatory Affairs from Temple University. In addition she is a licensed pharmacist and an adjunct professor for the School of Pharmacy/Quality Assurance-Regulatory Affairs at Temple University in Philadelphia, PA. Paul L. Pluta, Ph.D. Paul is a pharmaceutical scientist with technical development, manufacturing, and management experience. He has been involved in nearly all phases of pharmaceutical development and manufacturing including R&D formulation and process development, dissolution, stability, regulatory, quality assurance/control, compliance, specifications, scale-up, technology transfer, technical support, and validation/qualification. In his time at Abbott he had numerous new product and supporting regulatory submissions, as well as, extensive product technical support experience. Additionally, his validation experience includes manufacturing process validation, cleaning validation, and associated systems qualification including aseptic systems. He was also a practicing pharmacist for many years in community and hospital environments with direct involvement in preventing medication errors. He may be reached at paul.pluta@comcast.net. Voices in Validation brings you the best in validation and compliance topics. Voices in Validation is brought to you by IVT Network, your expert source for life science regulatory knowledge. For more information on IVT Network, check out their website at http://ivtnetwork.com.   

Canadian College of Healthcare and Pharmaceutics has launched a phlebotomy workshop. The 5-hour workshop teaches phlebotomy skills, and students receive a certificate upon completion. Go to https://cchap.ca (https://cchap.ca) to learn more.

Looking beyond Covid-19, the two Simons and Tim talk to Paul about the issues facing pharmaceutical companies, why GlaxoSmithKline is coming under pressure and one of the largest biopharma companies you may have never heard of…

Dr. Abisheak Sharma studied pharmacy and pharmacokinetics in India before coming to the United States to research under kratom expert Dr. Bonnie Avery. He now researches kratom with Dr. Christopher McCurdy at University of Florida as part of the Translational Drug Development Core. Dr. Sharma addresses the concern with kratom and other drug interactions, improved … 45. Dr. Abisheak Sharma, Pharmacokineticist and Kratom Researcher Read More » The post 45. Dr. Abisheak Sharma, Pharmacokineticist and Kratom Researcher first appeared on Kratom Science.

This article was originally published by Ioana Gherghescu and Begoña Delgado-Charro in Pharmaceutics 2021, 13(1) under a Creative Commons Attribution License. Abstract Biosimilar medicines expand the biotherapeutic market and improve patient access. This work looked into the landscape of the European and US biosimilar products, their regulatory authorization, market availability, and clinical evaluation undergone prior […] Source

Digitization Of Validation For Effective Off-Site Regulatory “Review” And “Inspection” This week, Stacey is joined by Ajaz Hussain, Alton Johnson, and Steve Thompson. As agencies like the FDA continue to rely on virtual inspection, we need to take a look at the process, including a review of documents and processes. How can these inspections be more hands-on and eyes-on, allowing for efficient and accurate outcomes?Resources from this episode Article - https://www.ivtnetwork.com/article/digitization-validation-effective-site-regulatory-%E2%80%9Creview%E2%80%9D-and-%E2%80%9Cinspection%E2%80%9D Dr. Ajaz Hussain, Ph.D., Advisory Board Chairman, ValGenesis, Inc.Dr. Hussain is globally recognized for his tireless efforts to improve the predictability of medicinal product development, manufacturing, and associated regulatory processes. As the Deputy Director Office of Pharmaceutical Science, he led some of the U.S. Food and Drug Administration's major initiatives to develop regulatory policies that already have and will continue to have, a significant impact on product development and approval in many geographies. His corporate experience includes leadership of the development and/or regulatory submissions of first-in-class Biosimilar, Follow-on Protein, and Complex Generic products at Sandoz. At Philip Morris International, he took on the challenge of higher levels of uncertainty (regulatory and business) and product complexity to build strategies and systems to successfully move forward development programs on plant-based vaccines, products for tobacco harm reduction, and ensure the credibility of scientific evidence to seek regulatory discussions and submissions. His experience at Wockhardt has helped him to understand the opportunities and talent companies in India have, the challenges they face, and how they can bring forward effective solutions to maintain and enhance competitiveness and credibility. He also has extensive teaching experience, he served as a tenured Associate Professor of Pharmaceutics at the University of Cincinnati, where he established a research program on Computer-Aided Formulation Design. Based on his broad experience in academia, US FDA, and industry he founded his consulting practice Insight Advice & Solutions LLC.Alton Johnson, Ph.D., Alton Johnson Consulting, LLCAlton Johnson is an industry leader and expert in pharmaceutical development, manufacturing, technology, and business solutions. In his current consulting role, he develops strategies and solutions for clients in the areas of new product development, manufacturing, digital transformation, pharmaceutical technology, business development, and compliance. He has 30-plus years of leadership experience at Pfizer across, Technical Services, Innovation, and Advanced Manufacturing Technology / Pharma 4.0. His extensive publications and presentations encompass Quality by Design, Risk Management, Knowledge Management, Validation, Process Analytical Technology, Continuous Processing, and Pharma 4.0, for organizations including ISPE, DIA, PDA, and AAPS. He has served in leadership roles for PhRMA, on the board of Smart Manufacturing Leadership Coalition, and as Chair of the Steering Committee for NIH-sponsored Engineering Research Center.Steven D. ThompsonSteve has over 20 years’ experience in life science working in Quality Assurance and Information Technology functions that span GxP regulations, both domestic and international. Steve has worked for start-ups and large multinational companies that include biotechnology, pharmaceutical, medical device, and cloud-based Software-as-a-Service (SaaS) solution providers. He is a published author, was certified as a PDA Systems Auditor in 2003, and is a regular speaker on industry trends and best practices.Voices in Validation brings you the best in validation and compliance topics. Voices in Validation is brought to you by IVT Network, your expert source for life science regulatory knowledge. For more information on IVT Network, check out their website at http://ivtnetwork.com.

Dr Bahijja Raimi-Abraham is a pharmacist, Lecturer in Pharmaceutics at King’s College London, Founder and Academic Lead of King’s College London Fight the Fakes. She also leads her own research group “The Raimi-Abraham Group”. Dr Raimi-Abraham's research to date has been in pharmaceutical materials and innovative manufacture. More recently she has focused her research efforts within the therapeutic and drug development aspects of malaria. In this episode we discuss power in academic life (and how to manage it), changing careers and leadership in research.

Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay. What is the first thing or picture strikes you when you hear terms familiar something like Pharmacognosy, Pharmacogenetics or Pharmacy, etc. You might have heard these so important and many more like these, I will tell you about these and all familiar important branches of pharmacology today. Talking firstly about Pharmacognosy, its the study of drug sources, it also covers identification of drugs from different sources like animal and plant origin. Second, Pharmacogenetics is study of differences/ variations and resulting changes in drug responses and drug metabolism, which can occur at individual and/or at population level.Depending on sensitivity of individual, what is developed is individual Drug therapy. Right example at right time explains the whole story well! Next word of thought is all dedicated to details about Pharmacogenomics in which genomic technology is used to explore more drug characteristics, a good example tells it all....Next set of information is all about Pharmacoeconomics, centred around cost effectiveness of drug and drug therapy. As I approach the end talks, I will disclose my real talks about practical aspect of the subject too, about Pharmacy, in disguise I will spill over discussion focus towards Pharmaceutics. Then I will shift the conversation string towards Clinical Pharmacy and Closing words will sing songs about Biopharmaceutics. I will give you a second to recollect and count the number of branches I told you all about today, give a try! Its countable on fingers, I am sure! With an indication to talk something different, new, crispy next time, I will call it for the day! For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!

Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay.What is the first thing or picture strikes you when you hear terms familiar something like Pharmacognosy, Pharmacogenetics or Pharmacy, etc. You might have heard these so important and many more like these, I will tell you about these and all familiar important branches of pharmacology today. Talking firstly about Pharmacognosy, its the study of drug sources, it also covers identification of drugs from different sources like animal and plant origin. Second, Pharmacogenetics is study of differences/ variations and resulting changes in drug responses and drug metabolism, which can occur at individual and/or at population level.Depending on sensitivity of individual, what is developed is individual Drug therapy. Right example at right time explains the whole story well! Next word of thought is all dedicated to details about Pharmacogenomics in which genomic technology is used to explore more drug characteristics, a good  example  tells it all....Next set of information is all about Pharmacoeconomics, centred around cost effectiveness of drug and drug therapy. As I approach the end talks, I will disclose my real talks about practical aspect of the subject too, about Pharmacy, in disguise I will spill over discussion focus towards Pharmaceutics. Then I will shift the conversation string towards Clinical Pharmacy and Closing words will sing songs about Biopharmaceutics. I will give you a second to recollect and count the number of branches I told you all about today, give a try! Its countable on fingers, I am sure! With an indication to talk something different, new, crispy next time, I will call it for the day!For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!

Welcome all to IS PHARMACOLOGY DIFFICULT Podcast! I am Dr Radhika Vijay. What is the first thing or picture strikes you when you hear terms familiar something like Pharmacognosy, Pharmacogenetics or Pharmacy, etc. You might have heard these so important and many more like these, I will tell you about these and all familiar important branches of pharmacology today. Talking firstly about Pharmacognosy, its the study of drug sources, it also covers identification of drugs from different sources like animal and plant origin. Second, Pharmacogenetics is study of differences/ variations and resulting changes in drug responses and drug metabolism, which can occur at individual and/or at population level.Depending on sensitivity of individual, what is developed is individual Drug therapy. Right example at right time explains the whole story well! Next word of thought is all dedicated to details about Pharmacogenomics in which genomic technology is used to explore more drug characteristics, a good example tells it all....Next set of information is all about Pharmacoeconomics, centred around cost effectiveness of drug and drug therapy. As I approach the end talks, I will disclose my real talks about practical aspect of the subject too, about Pharmacy, in disguise I will spill over discussion focus towards Pharmaceutics. Then I will shift the conversation string towards Clinical Pharmacy and Closing words will sing songs about Biopharmaceutics. I will give you a second to recollect and count the number of branches I told you all about today, give a try! Its countable on fingers, I am sure! With an indication to talk something different, new, crispy next time, I will call it for the day! For all the updates and latest episodes of my podcast, please visit www.ispharmacologydifficult.com where you can also sign up for a free monthly newsletter of mine. It actually contains lot of updates about the medical sciences, drug information and my podcast updates also. You can follow me on different social media handles like twitter, insta, facebook and linkedin. They all are with same name "IS PHARMACOLOGY DIFFICULT". If you are listening for the first time, do follow me here, whatever platform you are consuming this episode, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!

Welcome all to IS PHARMACOLOGY DIFFICULT Podcast ! I am Dr Radhika Vijay, if you are wondering what are the most broad and basic divisions of the subject Pharmacology, you will find it all in today's episode. Broadly, Pharmacology can be divided into Pharmacodynamics and Pharmacokinetics. Pharmacodynamics covers all details and lets us know ," What the drug does to the body?" On the other hand, Pharmacokinetics is the ADME study, it covers complete drug movement inside the body, telling about all the four processes in detail, Absorption, Distribution , Metabolism and Excretion. All in all, we get to know, "What body does to the drug?" With the help of two examples for each of these divisions, I will clearly describe the whole description and points. After telling you all about these broad pharmacological divisions, I will be throwing light on the Golden connection of Pharmaceutics, Pharmacokinetics, Pharmacodynamics and Pharmacotherapeutics. Its a chain connection step by step with a wonderful description so that you can memorize nicely and understand. fully. On this point of discussion, your query is definite to arise about other branches discussion which you know or you have. ever heard about. Well, no worries, with a promise to lighten up next school of thought with details about other branches, I will humbly depart today. For all updates and latest episodes, please visit www.ispharmacologydifficult.com. You can follow me on social media handles like twitter, insta, facebook and linkedin all with same names"Is Pharmacology Difficult". If you are listening for the first time, do follow me here on your favourite platform, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!

Welcome all to IS PHARMACOLOGY DIFFICULT Podcast ! I am Dr Radhika Vijay, if you are wondering what are the most broad and basic divisions of the subject Pharmacology, you will find it all in today's episode. Broadly, Pharmacology can be divided into Pharmacodynamics and Pharmacokinetics. Pharmacodynamics covers all details and lets us know ," What the drug does to the body?" On the other hand, Pharmacokinetics is the ADME study, it covers complete drug movement inside the body, telling about all the four processes in detail, Absorption, Distribution , Metabolism and Excretion. All in all, we get to know, "What body does to the drug?" With the help of two examples for each of these divisions, I will clearly describe the whole description and points. After telling you all about these broad pharmacological divisions, I will be throwing light on the Golden connection of Pharmaceutics, Pharmacokinetics, Pharmacodynamics and Pharmacotherapeutics. Its a chain connection step by step with a wonderful description so that you can memorize nicely and understand. fully. On this point of discussion, your query is definite to arise about other branches discussion which you know or you have. ever heard about. Well, no worries, with a promise to lighten up next school of thought with details about other branches, I will humbly depart today. For all updates and latest episodes, please visit www.ispharmacologydifficult.com. You can follow me on social media handles like twitter, insta, facebook and linkedin all with same names"Is Pharmacology Difficult". If you are listening for the first time, do follow me here on your favourite platform, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!

Welcome all to IS PHARMACOLOGY DIFFICULT Podcast ! I am Dr Radhika Vijay, if you are wondering what are the most broad and basic divisions of the subject Pharmacology, you will find it all in today's episode. Broadly, Pharmacology can be divided into Pharmacodynamics and Pharmacokinetics. Pharmacodynamics covers all details and lets us know ," What the drug does to the body?" On the other hand, Pharmacokinetics is the ADME study, it covers complete drug movement inside the body, telling about all the four processes in detail, Absorption, Distribution , Metabolism and Excretion. All in all, we get to know, "What body does to the drug?" With the help of two examples for each of these divisions, I will clearly describe the whole description and points. After telling you all about these broad pharmacological divisions, I will be throwing light on the Golden connection of Pharmaceutics, Pharmacokinetics, Pharmacodynamics and Pharmacotherapeutics. Its a chain connection step by step with a wonderful description so that you can memorize nicely and understand. fully. On this point of discussion, your query is definite to arise about other branches discussion which you know or you have. ever heard about. Well, no worries, with a promise to lighten up next school of thought with details about other branches, I will humbly depart today. For all updates and latest episodes, please visit www.ispharmacologydifficult.com. You can follow me on social media handles like twitter, insta, facebook and linkedin all with same names"Is Pharmacology Difficult". If you are listening for the first time, do follow me here on your favourite platform, stay tuned, do rate and review on ITunes, Apple podcasts, stay safe, stay happy, stay enlightened, Thank you!!

YOUR EYES DO NOT DECEIVE YOU! WE ARE FINALLY BACK WITH A NEW EPISODE! Arriving fashionably late to remote podcasting just eight months after everyone else, here we are. We promise it's been worth the wait for this one. Episode 16 sees Ella joined by the brilliant, hilarious and ACTUAL AWARD WINNING SCIENTIST Dr Bahijja Raimi-Abraham. Bahijja is a pharmacist, Lecturer in Pharmaceutics at King’s College London, Founder and Academic Lead of King’s College London Fight the Fakes. She also hosts the Monday Science podcast, and is an expert in drug delivery and global health. Aka, the perfect person to talk to right now. We discuss first periods (of course), how you even do a PHD, being creative with science, Tim Westwood, giving professional vagina advice and being in James Bond. Yep, Bahijja was in James Bond. We also talk about coronavirus and periods - how it’s affected some people’s cycles, and the research into COVID-19 and wider women's health currently taking place. You can find Bahijja on Twitter @DrBahijjaRaimiA, and her podcast Monday Science on Twitter @MondayScience_ and Instagram @MondayScience. The studies we talk about include: - 'The Impacts of Coronavirus on Women', Fawcett Society, https://www.fawcettsociety.org.uk/the-impacts-of-coronavirus-on-women - 'Sex differences in COVID-19 immune responses affect patient outcomes', Yale News, https://news.yale.edu/2020/08/26/sex-differences-covid-19-immune-responses-affect-patient-outcomes - 'Estrogen and COVID-19 symptoms: associations in women from the COVID Symptom Study', medRxiv, https://www.medrxiv.org/content/10.1101/2020.07.30.20164921v3 First Blood is a podcast about periods and puberty, hosted by Ella Woods. Get in touch at FirstBloodPodcastUK@gmail.com, and follow us on @FirstBloodPodcastUK on Instagram, @FirstBloodPodUK on Twitter. Thanks to Charlie Woods for the music.

How close are scientists to producing an effective vaccine for coronavirus? With more than 140 candidate vaccines now tracked by the World Health Organization, we speak to three key UCL researchers with expertise in biochemical engineering, bioethics and Pharmaceutics to find out what progress has been made and how we can make sure everyone has access to a vaccine when it's ready. Join Vivienne Parry as she explores this with UCL experts:• Prof Sarah Edwards (Professor of Bioethics, Dept of Science & Technology Studies)• Prof Eli Moore (Professor of Bioprocess Science & Enterprise, Dept of Biochemical Engineering)• Dr Sudaxshina Murdan (Reader in Pharmaceutics, UCL School of Pharmacy)For more info and transcripts, visit www.ucl.ac.uk/ucl-minds/podcasts/coronavirus See acast.com/privacy for privacy and opt-out information.

How close are scientists to producing an effective vaccine for coronavirus? With more than 140 candidate vaccines now tracked by the World Health Organization, we speak to three key UCL researchers with expertise in biochemical engineering, bioethics and Pharmaceutics to find out what progress has been made and how we can make sure everyone has access to a vaccine when it’s ready. Join Vivienne Parry as she explores this with UCL experts: • Prof Sarah Edwards (Professor of Bioethics, Dept of Science & Technology Studies) • Prof Eli Moore (Professor of Bioprocess Science & Enterprise, Dept of Biochemical Engineering) • Dr Sudaxshina Murdan (Reader in Pharmaceutics, UCL School of Pharmacy) For more info and transcripts, visit www.ucl.ac.uk/ucl-minds/podcasts/coronavirus

Lisa Carlton, PhD, understands rare childhood diseases both professionally and personally. She was already a scientist specializing in rare diseases when her daughter was diagnosed with one: tuberous sclerosis. As VP of Global Regulatory Affairs for a biotech drug developer she is involved in development of treatments for other rare diseases too. This makes her an ideal person to co-chair an industry-patient-advocacy group called the Working Group on Regulatory Science, a part of the EveryLife Foundation for Rare Disorders that seeks to advance the development of treatment and diagnostic opportunities for rare disease patients through science-driven public policy.Tuberous sclerosis, a rare genetic disorder, affects one in every 6,000 newborns in the United States. It is a disorder that causes benign growth in almost any tissue; it’s of particular concern when it occurs in the brain, lungs or kidneys. Some people who have tuberous sclerosis may have learning problems or difficult-to-control seizures. Her daughter—one of a pair of twins—was diagnosed in utero. She’s doing well, although the speech and language disorders associated with the condition have made it hard to access the curriculum in school. Dr. Carlton talks about the challenges of developing new treatments for rare diseases and the approaches taken to try to overcome them. She also talks about her daughter’s disease, and how families can bring their best to their journey as they adapt to support their child. Based on her experience as a parent and advocate—as well as her experience in the industry—she has this advice for families: “Take a breath.” Drug development is slow, especially in rare diseases. “You are in for a marathon of supporting your child.” When possible, connect with other parents and advocacy groups. Or build your own tribe—work, friends, family, etc. “You have to be healthy and rested enough to do this. You have to be at your best.” She’s often asked how she manages to keep going. “I don’t know how I wouldn’t do it. You’ve been given this gift of a special child. Now it’s time to find your tribe and push ahead.”Her advice for a biotech company considering launch of a clinical trial for a rare disease? Nobody knows more about a patient’s journey, the patient’s experience, than the patient—or a parent or caregiver. “Just listen to what patients are saying. You are going to learn a lot.”Lisa Carlton, PhD, has previously worked in regulatory roles at the National Institutes of Health, Otsuka Pharmaceuticals and International Partnership for Microbicides. She is currently serving as Vice President of Global Regulatory Affairs at REGENXBIO, a gene therapy-focused biotech company with headquarters in Rockville, MD. Lisa received her PhD in Pharmaceutics and MS in Medicinal Chemistry from the University of North Carolina in Chapel Hill and a BS in Biochemistry from North Carolina State University.

รายการ Dr.Amp Podcast เรื่องเล่าสุขภาพดี กับ หมอแอมป์ ตอน "5 สุดยอดวิตามินบำรุงผิว ตอนที่ 1" โดย นพ. ตนุพล วิรุฬหการุญ -ประธานเจ้าหน้าที่ปฏิบัติการ และ ผู้อำนวยการ BDMS Welness Clinic -ผู้อำนวยการ RoyalLife โรงพยาบาลกรุงเทพ -นายกสมาคมแพทย์ฟื้นฟูสุขภาพและส่งเสริมการศึกษาโรคอ้วน กรุงเทพ (BARSO)

The ALL ME® Podcast SARMs - What does the research say? - Dr. James Dalton Athletes are always looking for a competitive edge and many choose to take the clean approach in doing things the right by Training Hard, Eating Right, and Playing Fair. This is actually what we at the Taylor Hooton Foundation say is ALL ME. But there are those who look for ways to try and cheat the system by using a performance enhancing substance. Fairly new to the market is a product called Selective Androgen Receptor Modulators or SARMs, which was first introduced in 1998 as a non-steroidal therapeutic drug. Prohibited for use in all collegiate and professional sports, some athletes feel they may be a safer alternative to steroids. Why are SARMs banned for competition and are they safe to take? Are they a safer alternative to steroids and what does the research say about dosage? In this episode, I will be speaking with Dr. James Dalton who has spent over 20 years researching the effects of SARMs in clinical populations as well as exploring the potential side effects of SARMs, their safety, and whether or not he would recommend SARMs to his 19 year old son who was asking about their use and safety?   Dr. Dalton's Bio James T. Dalton, Ph.D. is Dean and Professor of Pharmaceutical Sciences in the College of Pharmacy at the University of Michigan.  He received his Bachelor of Science in Pharmacy from the University of Cincinnati (1986) and Doctor of Philosophy in pharmaceutics and pharmaceutical chemistry from Ohio State University (1990).  Dean Dalton rose through the faculty ranks in the Department of Pharmaceutical Sciences in the College of Pharmacy at the University of Tennessee (1992-2000) before returning to Ohio State where he served as Professor and Chair in the Division of Pharmaceutics (2000-2007).  He began an entrepreneurial leave of absence from Ohio State in 2005 and finally left OSU in 2007 to devote his full time effort as Chief Scientific Officer at GTx, Inc. in Memphis, TN (2007-2014) where he oversaw the preclinical and clinical development of selective androgen receptor modulators, which he will be talking about today.   He was recently elected to the National Academy of Medicine and is a Fellow of the American Association for the Advancement of Science (AAAS) and American Association of Pharmaceutical Scientists (AAPS).   He has co-authored over 300 original abstracts and peer-reviewed scientific manuscripts and is an inventor on over 400 United States and international patent applications related to selective androgen receptor modulators, selective estrogen receptor alpha and beta ligands, tubulin antagonists, and receptor tyrosine kinase inhibitors.  Resource Links:  Did You Know? The Taylor Hooton Foundation has an education program on Nutrition and Dietary Supplement Safety Up to 25% of Dietary Supplements are contaminated with illegal drugs and banned substances. Follow Us: Twitter:  @theTHF Instagram:  @theTHF Facebook: Taylor Hooton Foundation #ALLMEPEDFREE Contact Us:  Email:  Phone: 214-449-1990

My guest today, Jacob Cohen, is a cellular molecular biologist, who also has a degree in general chemistry. He specialises in the niche field of creating names for new pharmaceutical drugs that are being developed and produced.  This is a man that knows his stuff about viruses.  After explaining what he does for a living, I quiz Jacob with all the questions I've wanted to ask someone with this kind of knowledge.  Are branded drugs and generic drugs really the same? He clearly explains what is currently going on with the Coronavirus, how close we are to a cure, and when we can expect to end social distancing.  Jacob is obviously worried about how easily this virus spreads, but he emphasises how our focus should be on hygiene rather than a vaccine.  He understands this virus better than anyone else I've talked to, and after talking to him I feel like I understand it much better too… ”From a scientists point of view it's interesting, but scary. Mother Nature is literally the most diabolical serial killer there is.” – Jacob Cohen     Time Stamps: 01:09 – Who are guest today is. 01:49 – What Jacob does for a living. 08:03 – How they create the name for a new medication. 09:37 – The strange name requests they sometimes receive. 10:54 – If branded drugs and generic drugs are really the same. 13:30 – The competition within drug companies. 14:44 – The problems with generic drugs. 17:07 – How the process of getting names approved changes depending on where you are. 21:56 – Jacobs views on the current pandemic. 22:56 – The differences between bacteria and viruses. 25:54 – How Covid-19 works similar to the HIV virus. 30:54 – The different treatments that are already in development for Corona. 33:01 – What the Corona virus really is. 38:28 – How easy it is to convince yourself that you have a deadly disease. 41:47 – The moment Jacob knew how serious this virus was. 43:20 – The importance of social distancing, and how our immune systems work to fight against it. 51:38 – The difference in people's physical response to the virus. 53:33 – How the prevalence of the virus will shift with the seasons. 54:12 – The best thing you can do to avoid contracting the virus, and the problem with wearing gloves. 58:56 – The wake up call this should give people. 1:03:22 – The way knowledge around the virus is constantly shifting and evolving. 1:05:35 – The importance of supporting local businesses.    Resources:  www.texasrealfood.com Connect with Jacob Cohen: Facebook Connect with Patrick Scott Armstrong: Instagram Facebook

Dr. Karunya Kandimalla is Associate Professor in the Department of Pharmaceutics at the University of Minnesota and Research Collaborator at Mayo Clinic. His work focuses on macromolecular pharmacokinetics related to Alzheimer’s disease & metabolic syndrome, developing nanotech for diagnosis & treatment of cerebrovascular disease. https://www.pharmacy.umn.edu/bio/pharmaceutics-faculty/karunya-kandimalla LinkedIn ► https://linkedin.com/in/karunyakandimalla ******* Simulation is rebirthing the public intellectual by hosting the greatest multidisciplinary minds of our time. Build the future. Architect the frameworks and resource flows to maximize human potential. http://simulationseries.com ******* SUBSCRIBE TO SIMULATION ► YOUTUBE: http://bit.ly/SimYoTu ITUNES: http://bit.ly/SimulationiTunes INSTAGRAM: http://bit.ly/SimulationIG TWITTER: http://bit.ly/SimulationTwitter ******* FACEBOOK: http://bit.ly/SimulationFB SOUNDCLOUD: http://bit.ly/SimulationSC LINKEDIN: http://bit.ly/SimulationLinkedIn PATREON: http://bit.ly/SimulationPatreon CRYPTO: http://bit.ly/SimCrypto ******* NUANCE-DRIVEN DISCOURSE ► http://bit.ly/SimulationTG WATCH ALLEN'S TEDx TALK ► http://bit.ly/AllenTEDx FOLLOW ALLEN ► INSTAGRAM: http://bit.ly/AllenIG TWITTER: http://bit.ly/AllenT ******* LIST OF THOUGHT-PROVOKING QUESTIONS ► http://simulationseries.com/the-list GET IN TOUCH ► simulationseries@gmail.com

In this episode of Occupation Station, Dr. Thomas Garcia, Research Fellow in the Global Chemistry, Manufacturing, and Controls group at Pfizer talks about the exciting world of product development. Dr. Garcia, who is also an adjunct instructor in Pharmaceutics at ACPHS explains how his internship helped shape his journey and why he thinks mentorships are vitally important.

Lindsay and Catie discuss the importance of your personal brand, whether you own your own business or not. Coming from the physical sciences, Dr. Cat has found posting her research to social media leads to better reach, stronger connections, and higher recognition from colleagues. About Catie: Catie Leta aka Dr. rer. nat. Maren Katherina Preis is a licensed pharmacist from Germany, holds a Ph.D. in Pharmaceutics, and is a certified specialist for Pharmaceutical Technology. She received the award for the most outstanding doctoral thesis in Pharmaceutical Sciences 2014/2015 by the International Association for Pharmaceutical Technology in 2016 for her work about innovative oral drug delivery systems. Although everyone expected her to climb the academic ladder, Catie decided to follow her passions and turn them into a business: social media and fitness. Catie has always been a creative person and active on social media platforms. It all started with helping friends, colleagues and organisations to setup social media accounts to gain visibility in today's digital world. Today, she helps health and fitness coaches, but also aspiring scientists, to build their personal brands online like she did herself: "Social Like Catie" is the name of the program where she teaches her clients everything she learned in almost 10 years on social media. Besides all that, Catie is a passionate athlete and coach who offers strength- and powerbuilding programs for her clients. www.catieleta.com https://twitter.com/catieleta https://instagram.com/catieleta https://www.linkedin.com/in/mkpreis/ https://facebook.com/catieleta https://youtube.com/c/catieleta

Lindsay and Catie discuss the importance of your personal brand, whether you own your own business or not. Coming from the physical sciences, Dr. Cat has found posting her research to social media leads to better reach, stronger connections, and higher recognition from colleagues. About Catie: Catie Leta aka Dr. rer. nat. Maren Katherina Preis is a licensed pharmacist from Germany, holds a Ph.D. in Pharmaceutics, and is a certified specialist for Pharmaceutical Technology. She received the award for the most outstanding doctoral thesis in Pharmaceutical Sciences 2014/2015 by the International Association for Pharmaceutical Technology in 2016 for her work about innovative oral drug delivery systems. Although everyone expected her to climb the academic ladder, Catie decided to follow her passions and turn them into a business: social media and fitness. Catie has always been a creative person and active on social media platforms. It all started with helping friends, colleagues and organisations to setup social media accounts to gain visibility in today's digital world. Today, she helps health and fitness coaches, but also aspiring scientists, to build their personal brands online like she did herself: "Social Like Catie" is the name of the program where she teaches her clients everything she learned in almost 10 years on social media. Besides all that, Catie is a passionate athlete and coach who offers strength- and powerbuilding programs for her clients. www.catieleta.com https://twitter.com/catieleta https://instagram.com/catieleta https://www.linkedin.com/in/mkpreis/ https://facebook.com/catieleta https://youtube.com/c/catieleta

Regenerative Medicine Today welcomes Dr. Jelena Janjic. Dr. Janjic is an Associate Professor of Pharmaceutics in the Graduate School of Pharmaceutical Sciences and Mylan School of Pharmacy at Duquesne University. She is also the Founder and Co-Director of the Chronic Pain Research Consortium at Duquesne. Dr. Janjic discusses her research in chronic pain [...]

Fri, 13 Nov 2015 12:00:00 +0100 https://edoc.ub.uni-muenchen.de/18951/ https://edoc.ub.uni-muenchen.de/18951/1/Matthias_Philipp.pdf Matthias, Philipp ddc:540, ddc:500, Fakultät für Chemie und Ph

Lindsey Fountain talks to the editors of the new book Practical Pharmaceutics about how they updated this edition of book and how it is structured to help pharmacists with patient care. The project was financed by the EAHP and the Dutch pharmaceutical organisations KNMP and NVZA. The book was published by Springer in August 2015. For further information please visit http://www.eahp.eu/publications/textbookPractPharm or http://www.springer.com/gb/book/9783319158136.

The 1st half of the show we will be talking with William H. Frey II, Ph.D., Director Alzheimer's Research Center and Professor of Pharmaceutics, Neurology  and Neuroscience University of Minnesota about: What is Alzheimer's disease?  Why has it taken so long to find effective ways to treat and prevent Alzheimer's disease?  Intranasal insulin treatment and Stem cells Research and Dementia Contact Information- Alzheimer's Research Center 800-229-2872 Website: www.alzheimersinfo.org   The 2nd half of the show we will be talking with David Adelman is the Founder and CEO of Reel Tributes, and Claire Day, Vice President Constituent Services Alzheimer's Association Delaware Valley Chapter regarding “YOUR FAVORITE MEMORY CONTEST” The contest is being organized by the Alzheimer's Association Delaware Valley Chapter and Reel Tributes (www.reeltributes.com) This innovative contest will encourage families to write a short story about a memorable experience with their family member suffering from Alzheimer's disease. The website is www.reeltributes.com/memory. The contest video can be found at http://youtu.be/95TUvUV6x2g Contact info: Adelman@reeltributes.com www.reeltributes.com/memorySupport this Show: https://alzheimersspeaks.com/donate-now/See omnystudio.com/listener for privacy information.

➡️ For More Episodes, Visit: successstorypodcast.com➡️ Like The Show? Leave A Rating: https://ratethispodcast.com/successstoryToday, you'll hear me on the Super Entrepreneur Podcast hosted by Shahid Durrani, speaking about business, podcasting and startups.Make sure to subscribe the Podcast: https://www.youtube.com/@UC0-vd3aiWGCdsSHbj5zxsqg Tweet Me: twitter.com/scottdclaryMy Newsletter: newsletter.scottdclary.com/subscribeAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy